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ABSTRACT
DEVELOPING A PRECLINICAL MODEL OF HUMAN SUNITINIB CARDIOTOXICITY TO ASSESS THE ROLE OF
MECHANICAL LOADING USING ENGINEERED CARDIAC MICROTISSUES
Rachel Elizabeth Truitt
Kenneth B. Margulies, MD
Sunitinib, a multi-targeted oral tyrosine kinase inhibitor used to treat many solid tumors, has led to
important survival gains. However, this agent carries a significant risk of cardiotoxicity, with left
ventricular dysfunction reported in up to 9.7% of treated individuals, and hypertension in 11-43%. There
are a number of proposed mechanisms for sunitinib cardiotoxicity, however the relative contribution of
each remains poorly understood. In particular, the relationship between increased left ventricular
afterload toward inducing cardiac dysfunction remains unknown. Shortcomings of conventional cell
culture and rodent models have hampered the identification of pivotal mechanisms of cardiotoxicity such
as increased afterload. We instead chose to utilize a recently developed 3D in vitro microtissue model,
where rat myocytes self-assemble to form microtissues.
Our model of human sunitinib cardiotoxicity recapitulated characteristics observed by other research
groups, specifically, cardiomyocyte death, decreases in force generation and spontaneous beating, and
demonstrated the dependence of these characteristics on sunitinib dose and treatment duration.
Additionally, we observed decreases in mitochondrial membrane potential consistent with findings of
mitochondrial abnormalities in patient biopsies. We demonstrated that increased in vitro afterload
augments sunitinib cardiotoxicity. Finally, we created microtissues from cardiomyocytes derived from
human pluripotent stem cells and found that afterload is required for sunitinib induced apoptosis at
clinically relevant exposure concentrations.
Our finding that afterload is a key mediator suggests that anti-hypertensive therapy may be important for
avoiding eventual LV dysfunction in patients treated with sunitinib.
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ABSTRACT
DEVELOPING A PRECLINICAL MODEL OF HUMAN SUNITINIB CARDIOTOXICITY TO
ASSESS THE ROLE OF MECHANICAL LOADING USING ENGINEERED CARDIAC
MICROTISSUES

Rachel Elizabeth Truitt
Kenneth B. Margulies, MD
Sunitinib, a multi-targeted oral tyrosine kinase inhibitor used to treat many solid
tumors, has led to important survival gains. However, this agent carries a significant risk
of cardiotoxicity, with left ventricular dysfunction reported in up to 9.7% of treated
individuals, and hypertension in 11-43%. There are a number of proposed mechanisms
for sunitinib cardiotoxicity, however the relative contribution of each remains poorly
understood. In particular, the relationship between increased left ventricular afterload
toward inducing cardiac dysfunction remains unknown. Shortcomings of conventional
cell culture and rodent models have hampered the identification of pivotal mechanisms of
cardiotoxicity such as increased afterload. We instead chose to utilize a recently
developed 3D in vitro microtissue model, where rat myocytes self-assemble to form
microtissues.
Our model of human sunitinib cardiotoxicity recapitulated characteristics
observed by other research groups, specifically, cardiomyocyte death, decreases in force
generation and spontaneous beating, and demonstrated the dependence of these
characteristics on sunitinib dose and treatment duration. Additionally, we observed
decreases in mitochondrial membrane potential consistent with findings of mitochondrial
abnormalities in patient biopsies. We demonstrated that increased in vitro afterload
augments sunitinib cardiotoxicity. Finally, we created microtissues from cardiomyocytes
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derived from human pluripotent stem cells and found that afterload is required for
sunitinib induced apoptosis at clinically relevant exposure concentrations.
Our finding that afterload is a key mediator suggests that anti-hypertensive therapy may
be important for avoiding eventual LV dysfunction in patients treated with sunitinib.
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Chapter 1: Introduction
The rise of small molecule inhibitors targeting receptor tyrosine kinases (RTKs)
that regulate angiogenesis and proliferation has resulted in important gains in cancer
survival. However, many of these “targeted” therapies have unintended consequences on
the cardiovascular system. Sunitinib is a multi-targeted TKI that is used widely in the
treatment of renal cell carcinoma, gastrointestinal stromal tumors, and neuroendocrine
tumors and is currently under investigation in over 100 open clinical trials. Specifically,
as it relates to sunitinib, hypertension occurs in 11-43% of patients and left ventricular
(LV) dysfunction in 9.7%. These toxicities, although often manageable, can result in
dose delays, treatment interruptions, or dose reductions.
Cardiovascular toxicity with sunitinib has been hypothesized to be a result of offtarget inhibition of RTKs required for normal physiologic function. Sunitinib, used in the
treatment of many solid tumors, demonstrates inhibitory activity across a number of
RTKs including: vascular endothelial growth factor receptors (VEGFR1-3), platelet
derived growth factor receptor (PDGFR-B), FMS-like tyrosine kinase (FLT-3/CD135),
the stem cell receptor c-kit (KIT/CD117), and 5' AMP-activated protein kinase (AMPK),
all of which have been shown to be either cardioprotective during times of stress or
important for maintaining cardiovascular homeostasis. However, the relative
contributions of each of these factors remains poorly understood. In particular, the direct
effects of increased afterload on cardiac function in the setting of sunitinib remain
speculative. Given the established link between increased afterload and the eventual
development of LV dysfunction, we hypothesized increased afterload will augment the
cardiotoxic effects of sunitinib.
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Testing the hypothesis that increased afterload exacerbates sunitinib toxicity
would require a large in vivo clinical trial and substantial expense, and may face various
ethical roadblocks if we were to have cohorts of patients with uncontrolled hypertension.
Current in vitro cell culture and animal models suffer from limitations that minimize their
usefulness for modeling human sunitinib cardiotoxicity. The overall goal of this thesis
was to create a preclinical model of human sunitinib cardiotoxicity using an in vitro
microtissue model in which 3D cardiac microtissues (CMT) from neonatal rat
cardiomyocytes self-assemble on silicone (PDMS) cantilevers. We used this system to
characterize sunitinib cardiotoxicity using metrics for cell viability, mitochondrial
dysfunction and contractile function, and examined how these characteristics are
impacted by sunitinib dose, treatment duration, and degree of loading. We also performed
preliminary experiments using CMTs composed of human pluripotent (iPS) derived
cardiomyocytes and compared our results to neonatal rat CMT results.
The organization of this thesis is as follows: Chapter 2 provides background
information on tyrosine kinase inhibitors and how we evaluate their cardiotoxic effects,
such as hypertension and LV dysfunction, in a clinical setting. Next, we specifically focus
on sunitinib, and discuss its observed cardiotoxic effects in patients and our current
insights into the primary mechanisms governing sunitinib cardiotoxicity. We also discuss
some of the limitations with current models being utilized to assess sunitinib
cardiotoxicity. The final part of chapter 2 focuses on how we can take advantage of recent
advances in human pluripotent stem cell derived cardiac cell types and tissue engineering
to create novel preclinical models for evaluating drug induced cardiotoxicity.
Chapter 3 describes the experimental methods utilized for this thesis. We included
information about isolation and cell culture techniques for both neonatal rat cardiac cell
types as well as information on human pluripotent culture and cardiac differentiation
2

methods. We also discuss microfabrication and seeding protocols for creating cardiac
microtissues (CMTs). In the final part of this chapter, we discuss analytical methods used
for detecting cell viability, cardiac function, and mitochondria function (membrane
potential, ATP levels).
Chapter 4 discusses the in vitro model established to study sunitinib
cardiotoxicity. Using the rat microtissue model, we characterized sunitinib cardiotoxicity
in terms of its effects on cell viability and CMT function. We looked at caspase 3/7
activation and late apoptosis/necrosis to characterize cell viability. When examining
effects on cardiac function, we analyzed changes in tissue force generation (diastolic and
systolic) as well as electrophysiology (spontaneous beating rate, excitation threshold,
maximum capture rate). We assessed the dependence on these factors on sunitinib dose
and/or treatment duration.
In Chapter 5 we focused on elucidating some of the mechanisms of sunitinib
cardiotoxicity. As mentioned above, we hypothesized that increased afterload would
augment sunitinib cardiotoxicity. We created microtissues under different degrees of
afterload using CMT model by changing the material properties of the pillars, which
serves as the major source of afterload, and assessed caspase 3/7 activation in response to
sunitinib treatment. We also examined changes in mitochondria function in response to
sunitinib. Specifically we looked at differences in mitochondrial membrane potential in
rat cardiomyocytes, and evaluated the dependence of this response on treatment duration.
To see how changes in mitochondria function affect downstream energy production, we
also measured cellular ATP levels. Finally, we evaluated the ability of an AMPK
activator to reverse sunitinib induced caspase activation.

3

In Chapter 6 we show preliminary results with human CMTs created from
pluripotent stem cells derived cardiomyocytes (iPS-CMs). We evaluate caspase 3/7
activation with sunitinib treatment and compared our findings to rat CMTs. We also
measured caspase 3/7 levels in human CMTs subjected to different degrees of afterload to
determine whether increased afterload augments sunitinib cardiotoxicity in human cells.
Chapter 7 summarizes the results of the present work and discusses their clinical
relevance. We also outline future research plans for this project.
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Chapter 2: Background Information

2.1 Tyrosine Kinase Inhibitors and their Cardiotoxic Effects
2.1.1 Development of Tyrosine Kinase Inhibitors (TKIs) as Anti-Neoplastic Agents:
Tyrosine Kinase Inhibitors (TKI’s) entered the drug landscape at a time when
researchers were looking for more targeted therapies for treating cancer, as such drugs
were predicted to have less overall toxicity compared to conventional anti-neoplastic
treatments (anthracyclines, anti-metabolites) that were currently available on the market.
Advances in genomics as well as our understanding of cell signaling networks allowed
researchers to elucidate the differences between healthy and cancerous cells. From this
body of research, receptor tyrosine kinases (RTK) emerged as a therapeutic target, as
many cancers were found to be associated with erroneous activation of these receptors
[Gschwind et al. 2004]. This finding was confirmed on the DNA level [Robinson et al.
2000]. RTKs play a major role in signaling networks associated with normal cell function,
regulating processes associated with growth and differentiation, and are present in most
tissues [Lodish et al. 2000]. Because cancer is associated with erroneous activation of
these receptors, anti-neoplastic drugs were targeted towards partially silencing these
RTKs, and hence the class of TKI drugs was born. The amount of cancer research
dedicated to identifying effective TKI’s has increased dramatically since 1970 (Figure 2.1
panel A) [NCBI, PubMed].
The first TKI to be approved by the FDA was tratstuzmab (Herceptin®,
Genentech); a humanized mouse monoclonal antibody targeted against the human RTK
epithelial growth factor 2 receptor (EGF2/ERbB2) in 1998 [Paul MK et al. 2004]. Its
primary use was to treat metastatic breast cancer. Since the approval of tratstuzmab, there
5

have been 27 TKIs approved by the FDA for a variety of different solid tumors (breast,
colon, renal, etc.) since 2001(Fig 2.1 panel B) [Wu et al. 2015].

Figure 2.1: The rise of Tyrosine Kinase Inhibitors (TKIs). A) Article count of TKI
research in field of cancer over time (NCBI, PubMed). B) Timeline of FDA approval of
protein and lipid kinase inhibitors. Reprinted from Trends in Pharmacological Sciences:
P. Wu et al, “FDA-approved small-molecule kinase inhibitors”, Volume 36 Issue 7, 42229, Copyright 2015 with permission from Elsevier. License no. 3980390063464

TKI drugs can either be single-targeted or multi-targeted. Looking at equilibrium
dissociation constants (Kd) across a number of different substrates is useful for
determining TKI specificity, with lower Kd constants being associated with increased
binding affinity. In the figure below the authors determined dissociation constants for
6

numerous chemotherapy agents across numerous kinases (Figure 2.2) [Fabian et al.
2008]. Drugs like Lapatinib (labeled as GW-2016) only show binding affinity for a few
substrates indicating a high degree of specificity. On the other hand, drugs like
staurosporine and sunitinib (labeled as SU11248) have the ability to bind to numerous
targets, giving them lower degrees of specificity. Multi-targeted TKIs with a low degree
of specificity such as sunitinib have the potential to become problematic, as the drug may
interfere with kinase activity required for normal physiological function, thus leading to
unwanted side effects such as cardiotoxicity [Broekman et al. 2011]. Currently, there are
over 300 open clinical trials [clinicatrials.gov] focused on TKI’s and tens of thousands of
patients receiving these drugs, hence their impact will continue to grow, so it is important
to identify any potential negative side effects associated with these drugs so we can
maximize their use and safety.

7

Figure 2.2: Specificity profiles of various chemotherapy compounds. A plot of
dissociation constants (Kd) of chemotherapy agents against a variety of target molecules.
[Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer Research
UK: Nature Biotechnology, Miles A Fabian, William H Biggs, Daniel K Treiber, Corey E
Atteridge, Mihai D Azimioara et al., “A small molecule kinase interaction map for
clinical kinase inhibitors” Vol. 23 Issue 3: Copyright (2008); License no.
3979410866899]
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2.1.2 Types of Cardiotoxicity
One major consequence of chemotherapy can be cardiotoxicity. Cardiotoxicity is
defined as dysfunction relating to the heart (ischemia, arrhythmias, heart failure,
myocarditis, pericarditis), as well as alterations in hemodynamics (hypertension, acute
coronary syndrome) [Rodriguez 2015]. We will primarily focus our discussion on
arrhythmias, hypertension, and heart failure as they are the most prevalent forms of
chemotherapy induced cardiotoxicity observed in the clinic.

2.1.2.1 Arrhythmias:
Arrhythmias are defined as any abnormality in the heart’s electrical system that
results in an abnormal heart rhythm. These electrical impulses may happen too quickly,
too slowly, or erratically – causing the heart to speed up, slow down, or beat erratically
[The American Heart Association Sept 2016]. The main consequence of this abnormal
beating is ineffective pumping of blood to the rest of the body. While most arrhythmias
are harmless, some can be life threatening, such as long QT syndrome, a condition that
causes prolongation of the QT interval resulting from a mutation(s) in one or more ion
channels (sodium, potassium, or calcium) [The American Heart Association Sept 2016].
In the context of drug development, identifying any changes in the QT interval is vital as
a measure of the pro-arrhythmic potential of a candidate drug [FDA Center for Drug
Evaluation and Research (CDER) 2005]. Pre-clinical studies utilizing mammalian cells
(CHO, HEK293) transfected with the human Ether-à-go-go-Related Gene (hERG;
potassium ion channel) and large animal models are widely utilized to assess the proarrhythmic potential of drugs [FDA CDER 2005], but have their limitations as we will
explain later. Later in the drug approval process, arrhythmias are closely monitored
9

during clinical trials with healthy and diseased patients. Despite these efforts,
chemotherapy induced arrhythmias are still an issue today. Table 2-1 gives a detailed list
of the types of arrhythmias and which chemotherapy agents are associated with causing
these arrhythmias [Tarmargo et al. 2015]. To summarize, atrial fibrillation occurs in
patients taking alkylating agents, cisplatin, and anti-metabolites (7.9-10%, 12-32%, 0.5512% respectively). Taxanes have a high incidence of sinus bradycardia (slowing of heart
beat), about 30% according to the National Cancer Institute [Tarmargo et al. 2015].
Treatment with anthracyclines carries a risk, about 24%, of premature ventricular
contractions [Tarmargo et al. 2015]. As for tyrosine kinase inhibitors, many have been
demonstrated to block hERG channel, however their effects on QT prolongation are mild
(<15ms) and the overall occurrence of arrhythmias is low (<2%) [Tarmargo et al. 2015;
Shah RR et al. 2014&2015]. Large effects on the QT interval (>500ms) have been
observed in <2.3% of patients for the TKI sunitinib [Shah RR et al 2014&2015].
Additionally there have been only isolated cases of atrial fibrillation with TKI therapy
[Tarmargo et al. 2015; Shah RR et al. 2014&2015]. In summary, arrhythmia disorders
are often times a consequence of chemotherapy treatment, but depending on the agent, the
type and risk of arrhythmias can vary significantly.
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Table 2-1: Types of cardiac arrhythmias induced by chemotherapy drugs. [Original
Source: Drug Safety, Cancer Chemotherapy and Cardiac Arrhythmias: A Review,
Volume 38 Issue 2, 2015, Juan Tamargo. Reproduced with permission from Springer:
License no. 3979440363625]

2.1.2.2 Hypertension and its Link to Cardiac Function
Hypertension is a relatively common cardiovascular toxicity caused by
chemotherapy. Hypertension is defined as a systemic blood pressure greater than 140/90
mmHg. Increased blood pressure can cause damage to arteries, leading to long-term
consequences including abnormal vasomotion, atherosclerosis, and ultimately result in
inadequate blood flow to organs (heart, kidneys, brain) and increase the risk for
myocardial infarction, kidney failure, and stroke [The American Heart Association Oct
2016]. TKI’s are especially known for inducing hypertension, as many of these drugs
were designed to inhibit angiogenesis, via vascular endothelial growth factor receptor
(VEGFR) and/or platelet derived growth factor receptor (PDGFR) inhibition. Thus, TKIs
11

carry a high risk for causing vascular dysfunction and increased oxidative stress [Shah RR
et al 2015; Chintalgattu et al. 2010; Di Siena et al. 2016; Zentilin et al. 2010]. Studies
report an 11-43% incidence of hypertension with anti-angiogenic TKI therapy [Guverich
et al. 2009]. These patients have a 7-8 fold increased relative risk for hypertension
[Guverich et al. 2009]; thus blood pressure should be monitored during a patient’s
treatment with TKI therapy.
Increased blood pressure also has direct effects on the heart. The left ventricle of
the heart, the “pump” responsible for ejecting blood into the aorta, must generate enough
pressure to match circulating blood pressure in order for aortic valve to open and eject
blood. Thus, during a hypertensive state, ventricles are required to generate more systolic
(active) force. We use the term afterload to describe the external load the myocardium
(heart) must overcome before shortening (ejection) can begin [Norton JM 2001].
Therefore hypertension causes increased afterload on the heart. This is significant because
increased demands for force generation will also have effects on the amount of volume
pumped out by the ventricle (stroke volume, SV) [Klabunde 2015]. Figure 2.3 (panel A)
depicts what is known as the force-velocity relationship for cardiac muscle. When force is
at a maximum, such as when the heart is under high degrees of afterload, contraction
velocity is approaching zero. As the amount of afterload/force decreases, the velocity of
contraction increases. Therefore if the ventricle is forced to pump harder, it can’t pump as
quickly and less blood ultimately gets ejected, hence stroke volume decreases (Figure 2.3
panel B) [Klabunde 2015]. If not compensated for, this would be a major problem as
organs wouldn’t be receiving enough blood. Luckily hearts have another mechanism to
compensate for decreased SV due to increased afterload. The increased volume of blood
remaining in the ventricle due to the afterload increase will cause the ventricle to stretch
more during filling process; this stretch on the ventricle is called preload. According to
12

the Frank-Starling mechanism, this increase in preload will lead to increase in stroke
volume [Brady JM 1991]. Hence, increases in afterload can be partially compensated for
by increases in preload. However, if a patient has defects in the Frank-Starling
mechanism due to an underlying cardiovascular condition, a hypertensive (increased
afterload) state could be lead to decreased cardiac output and left ventricular dysfunction,
which I will be discussing in the next section [Fernandes-Silva et al. 2016; Ozkan et al.
2011].

Figure 2.3: Effect of Afterload on Cardiac Force Generation. A) Force-Velocity
Relationship. B) Increased afterload decreases stroke volume (SV) which results in
increased filling pressures (LVEDP) during next cardiac cycle. [Original Source: Richard
E. Klabunde, CV Physiology 2015. “Cardiac Afterload” and “Cardiac Muscle Force and
Velocity Relationship” www.cvphysiology.com ]
13

2.1.2.3 Left Ventricular (LV) Dysfunction
The previous section already alluded to one mechanism for LV dysfunction,
through hypertension and its resulting effects on the heart. There are a number of factors
that can contribute to LV dysfunction both genetic and environmental. Chemotherapy
treatment, for example, carries a risk of killing cardiac myocytes via apoptosis; this loss
of cells puts more workload on the remaining cells. The ventricle chamber expands and
dilates in an effort to normalize stresses, however ultimately normal cardiac output cannot
be restored (Figure 2.4 panel A) and the patient develops heart failure. There are a
number of additional factors contributing to development of heart failure such as
sustained activation of neurohumoral systems that ultimately induce maladaptive changes
in individual cardiac myocytes, inflammatory factors, myofibroblast
differentiation/fibrosis, and changes in cardiac metabolism [Minguell ER 2004; Fan D et
al. 2012; Kolwicz SC et al. 2013]. In the case of myocardial infarction or chemotherapy
induced toxicity, the initial loss of myocytes initiates a cascade of maladaptive
remodeling that ultimately results in heart failure. Heart failure is usually classified by the
severity of the patient’s symptoms. Figure 2.4 (panel B) shows the New York Heart
Association’s (NYHA) heart failure classification system:
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Figure 2.4: Progression of Heart Failure. A) Development of heart failure after
hemodynamic overloading. [Reprinted by permission from Macmillan Publishers Ltd:
Nature Reviews Cardiology (Ziad Taimeh, John Loughran, Emma J. Birks and Roberto
Bolli, “Vascular endothelial growth factor in heart failure” Vol. 10 Issue 9, Copyright
(2013). License No. 3979440910127] B) NYHA Classification of Heart Failure. [Source:
ReliantHeart Inc., “Left Ventricular Dysfunction.” http://reliantheart.com/left-ventricledysfunction/]

The overall incidence of all-grade and high-grade chronic heart failure associated
with anti-angiogenic (VEGFR) TKIs was 3.2 % (95 % CI 1.8–5.8) and 1.4 % (95 % CI
0.9–2.3) [Shah RR et al. 2015], respectively. A meta-analysis of randomized phase II and
III clinical trials of patients with solid tumors receiving sunitinib, axitinib, cediranib, or
15

regorafenib reported a relative risk of all-grade cardiac dysfunction to be 2.36 (95 % CI
0.95–5.87; p = 0.06). [Shah RR et al. 2015]

2.1.2.4 Distinguishing Direct and Indirect Mediators of TKI Induced Cardiotoxicity
The previous sections discussed the various ways in which cardiotoxicity from
chemotherapy treatment can present itself (arrhythmias, hypertension, and LV
dysfunction). What isn’t discussed or studied as frequently is whether cardiotoxicity is
due to: 1) intrinsic toxicity of the chemotherapy agent, or 2) indirect effects, such as
toxicity to a different organ system. In the case of TKIs, many induce hypertension due to
their anti-angiogenic properties, and, as I discussed above, hypertension can cause LV
dysfunction. However, depending on the drug’s RTK specificity, the drug could also be
directly toxic to cardiac myocytes by disrupting their own RTK dependent pathways,
which can result in LV dysfunction. So a major question arises; what are the relative
contributions of hypertension (i.e. increased afterload) and intrinsic toxicity to LV
dysfunction? We will attempt to answer this question in Chapter 5 of this dissertation,
which explicitly looks at toxicity induced by sunitinib under varying degrees of afterload.
2.1.3 Diagnosing and Monitoring Cardiotoxicity in the Clinic
Despite the prevalence of chemotherapy-induced cardiotoxicity, there are
currently no specific guidelines for treating and monitoring it [Albini et al. 2010].
Nevertheless, the field of cardio-oncology has emerged in response to the complex
decision making necessary to balance the benefits and risks associated with treating
cancer. Cardio-oncologists rely on a battery of tests (imaging, biopsy, biomarkers in
blood) in order to formally diagnose patients with chemotherapy induced cardiotoxicity.
This section will review some of these methods and how they relate to diagnosis criteria.
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2.1.3.1 Methods for Diagnosing Chemotherapy Induced Cardiotoxicity
Endomyocardial biopsy remains the most sensitive method for detecting
cardiotoxicity, although it is also the most invasive method. With this method, small
samples of heart tissues are analyzed for distortions in myocyte organization.
Electrocardiograms and Echocardiograms (2D or 3D) are utilized more often in the clinic
as they are far less invasive. Electrocardiograms can reveal dysfunction in the heart’s
electrical activity, and thus are useful for detecting arrhythmias, which can be side effects
of certain chemotherapy regimens. Echocardiograms, on the other hand, are useful for
looking at diastolic (filling) and systolic (pumping) function of the heart and the
morphology of the heart’s chambers and valves. Echocardiograms are frequently used to
calculate and monitor the ejection fraction of the left ventricle (LVEF); which represents
the fraction of blood pumped out of the heart relative to the amount that of blood in the
chamber at the end of filling (systolic function). Normal LVEFs typically range from
55%-65%, and significant decreases (>10%) over time are associated with LV
dysfunction. One major disadvantage of looking at LVEF is that declines often times do
not occur until later stages of cardiotoxicity. Ideally we would like to identify
cardiotoxicity at its earliest stages. [Pizzino F et al. 2014; Sawaya H et al. 2012].
Next, we will discuss some emerging technologies for early detection of
cardiotoxicity (i.e. precedes declines in LVEF). One of these techniques is called speckletracking imaging. This method focuses on analyzing the 3D twisting and torsion
deformations that occur during contraction by tracking natural acoustic and inference
patterns called “speckles” within an ultrasonic window. The deformation between
speckles within a region is calculated, obtaining a value referred to as strain. The velocity
of strain is defined as strain rate. Several studies have looked at variations in strain and
strain rate in patients receiving chemotherapy and found that these values are early
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predictors of eventual declines in LVEF. Magnetic Resonance imaging can also be
utilized for tissue characterization to detect things like early fibrosis by administering
gadolinium and looking for late gadolinium enhancement. Late gadolinium enhancement
is when a tissue presents slow contrast wash-out, which is usually a sign of scar
tissue/fibrosis. Early alterations of late gadolinium enhancement have been described in
chemotherapy-treated patients and are predictive of declines in LVEF. [Pizzino et al
2014].
The final technique we would like to discuss is the use of biomarkers. The
presence of cardiac specific proteins such as cardiac troponin is indicative of cardiac
damage [Yu EF et al 2016]. Elevations in troponin levels are usually used to diagnose
myocardial infarction (heart attacks). Troponin levels measured after chemotherapy
treatment have been shown to be predictive of later cardiotoxicity, as has
myeloperoxidase, with the combination of these two biomarkers representing the highest
risk for future cardiac dysfunction [Pizzino et al 2014]. However, these studies were
conducted with small patient populations and larger studies are required to confirm these
results. Biomarker testing is relatively non-invasive and easy to perform and analyze.
In summary, there are a variety of methods for detecting cardiotoxicity, with some
new emerging technologies that may allow for detecting very early signs of
cardiotoxicity, specifically those that precede LVEF decline. Ideally, cancer patients
should get testing done before treatment to get baseline levels of biomarkers (troponin)
and LVEF and have these quantities monitored during and after treatment [Yu EF et al.
2016]. This is especially important if the patient has a previous history of cardiovascular
disease, as it has been shown that patients who experience the most adverse cardiac
outcomes following chemotherapy treatment are ones who had underlying cardiovascular
disease before treatment [Albini et al. 2010].
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2.1.3.2 Diagnosis Criteria for Chemotherapy Induced Cardiotoxicity
The Cardiac Review and Evaluation Committee (CREC) defines chemotherapyinduced cardiotoxicity as the presence of at least one of the following elements: [Pizzino
et al. 2014]
1. Cardiomyopathy characterized by a decrease in LVEF
2. Symptoms of congestive heart failure (see NYHA guidelines)
3. Associated signs of congestive heart failure such as but not limited to:
tachycardia or S3 gallop.
4. Decline of LVEF of at least 5% to below 55% with accompanying signs of
congestive heart failure; or a decline of LVEF of at least 10% to below
55% without accompanying symptoms.
2.1.3.3 Categories of Chemotherapy Induced Cardiotoxicity
Cardiac dysfunction due to chemotherapy can be divided into three categories: 1)
acute, 2) subacute, or 3) chronic. Acute or subacute cardiotoxicity can develop any time
from the start of treatment up to 2 weeks after the completion of chemotherapy. Chronic
cardiotoxicity, on the other hand, might not present itself until almost a year after the
completion of treatment (early cardiotoxicity) or more than one year after treatment (late
cardiotoxicity). This further reinforces the notion that patients should be monitored
(biomarkers, LVEF measurements), not just during treatment, but also for a significant
amount of time after treatment. Additionally, methods for pre-treatment testing with
predictive value may be worth developing [Albini et al. 2010].
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2.2 Sunitinib Malate: A Tyrosine Kinase Inhibitor with Cardiotoxic
Effects

2.2.1 Mechanism of Action
Sunitinib (SU11248) was originally developed by a small biopharmaceutical
company named SUGEN, after three of their other PDGF inhibitors failed in clinical trials
(1994-1999). Two acquisitions later, sunitinib became the property of Pfizer who finished
phase III clinical trials for the drug. Eventually, the drug was approved in January 2006
for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumors
(GIST) [NIH/National Cancer Institute]. Originally designed as a PDGFR inhibitor to
target tumor angiogenesis, sunitinib actually exhibits inhibitory behavior across a number
of RTKs associated with angiogenesis such as VEGFR1-3, PDGFR(a, b), FMS related
tyrosine kinase (FLT-3), and the stem cell receptor KIT [O’Farrell et al. 2003; Faivre et
al. 2007]; . Compared to similar TKIs available at the time, such as Gleevec (imatinib),
sunitinib had more of a multi-targeted effect [Fabian et al 2008]. This attribute could
explain why sunitinib successfully treated tumors that were resistant to Gleevec [Demetri
et al. 2006]. Currently, more than 100,000 people have been treated with sunitinib, and
there are over 100 open clinical trials with this drug [clinicaltrails.gov]. This fact stresses
the notion that we need to better our understanding of sunitinib cardiotoxicity, as even
more people will be treated with this drug in the future.
2.2.1 Clinical Incidences of Sunitinib Cardiotoxicity
Early incidences of cardiotoxicity were observed during phase I B trials with
leukemia (AML) patients when researchers were trying to determine dosage and safety. In
a trial of 16 patients given sunitinib (50mg or 75mg dose), the 2 patients given the 75 mg
dose experienced grade 4 hypertension and one patient developed heart failure (after
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suffering a myocardial infarction) and died “due to cardiac insufficiency”. The authors
commented that they believe this death could have been related to sunitinib treatment. As
a result of this cardiotoxicity, the authors concluded that 50mg is the maximum tolerable
dose for these patients. [Fiedler et al. 2005]
Cardiovascular toxicity of sunitinib was also reported during numerous Phase III
clinical trials. In one study, GIST patients taking 50mg of sunitinib per day reported cases
of Grade 1/2 (15 patients/8%) and Grade 3 hypertension (6 patients/ 3%). There were no
reported cases or heart failure with 50mg dose [Demetri et al. 2006]. However in two
separate phase III trials, there were reports of LV dysfunction. Telli and colleagues
reported that 7 out 48 enrolled patients experienced grade 3 or 4 symptomatic LV
dysfunction anywhere from 22 to 435 days after treatment. Three of those patients
continued to experience heart failure even after sunitinib was removed and they began
treatment for heart failure. The authors noted that a history of cardiovascular disease was
a major factor in this result [Telli et al 2008]. Along these lines, Hall and colleagues
published results from a phase III trial with sunitinib where they defined the number of
patients with either hypertension or LV dysfunction, both before and after treatment.
These results are plotted below in Figure 2.5. [Hall et al. 2013].
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Figure 2.5: Hypertension and LV Dysfunction following treatment with sunitinib.
Number of patients with various grades (0-4) of hypertension (left) and/or LV
Dysfunction (right) before (blue) and after (red) treatment with sunitinib. Figures were
created using data from Table 2 of G. DiLorenzo et al. Ann. Oncol. 2009.

This figure shows a general trend towards worsening degrees of both hypertension
and LV dysfunction following sunitinib treatment. These studies as a whole not only
demonstrate the potential for adverse cardiovascular outcomes with sunitinib, they also
serve as an example of how factors like medical history can play a role in whether or not
a patient will develop cardiotoxicity. These confounding factors highlight the need for
more standardized screening methods for drug toxicity in human cells. Chapter 4
discusses the creation of a preclinical tissue culture platform that can be combined with
human cells to assess the toxicity of candidate drugs.
2.2.1 Insights into the Molecular Mechanisms of Sunitinib Cardiotoxicity
2.2.1.1 Animal and In Vitro Cell Culture Study Design
Following reports of cardiotoxicity during human clinical trials, researchers aimed
to gain a better understanding of 1) sunitinib toxicity at the cardiomyocyte level and 2)
the underlying mechanisms governing this toxicity. One obvious cause of cardiotoxicity
22

could be off-target inhibition of angiogenesis in the heart. As mentioned earlier, sunitinib
can inhibit a variety of TKI’s associated with angiogenesis (VEGFR1-3, PDGFR-A/B,
FLT-3, and the stem cell receptor KIT). It is widely recognized that many, if not all, of
these receptors are critical for maintaining cardiovascular homeostasis and/or protecting
the heart during times of increased stress. In this next section I will discuss studies that
aimed to elucidate effects of sunitinib on cardiomyocytes and identify some key signaling
pathways involved in this response.
The majority of these studies employed either adult mice or primary rat
cardiomyocyte cell cultures. One study I will discuss utilized human atrial muscle strips.
The doses of sunitinib typically utilized in these studies ranged from 0.1-250µM (mostly
1-10µM range) from cell culture studies and 20mg/kg -100 mg/kg per day for animal
studies. To put these doses into perspective, a 50 mg/day treatment regimen for a patient
results in average sunitinib concentrations in the blood (plasma) at around 0.1-0.2µM with
peak plasma concentrations at 2µM sunitinib [Faivre et al. 2005; Harvey and Leinwand
2015]. In view of this, some experiments appear to utilize doses that are outside the
physiological range. Some of the metrics used for characterizing sunitinib toxicity in
these include:
1. Apoptosis: Caspase 3/7, 9 activation, TUNEL, cytochrome C release
2. Cell Viability: LDH release, mitochondrial morphology
3. Metabolism and Energetics: ATP levels, lipid drop formation
4. Functional: EF, blood pressure, calcium transients, contractile reserve
Alterations in cell signaling were also examined in many of these studies. Those findings
will be discussed later in this section.
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2.2.1.2 Results from Animal Studies: Insights into Afterload as a Possible Mediator of
Sunitinib Cardiotoxicity
In studies using adult mice treated with sunitinib, mitochondrial morphology
changes (swelling) could be observed with as little as 10 mg/kg per day of sunitinib [Chu
et al. 2007]. Cardiac myocyte hypertrophy was observed with 25 mg/kg per day sunitinib,
however neither hypertension nor LV dysfunction were observed at this dose. However, if
phenylephrine (PE) was administered concurrently with sunitinib (25 mg/kg), there were
signs of cardiomyocyte apoptosis, measured by caspase activation [Chu et al. 2007;
Kerkela et al. 2007]. This is an interesting finding as PE can increase blood pressure,
which would increase the amount of afterload on the heart. This result suggests that
sunitinib toxicity might be dependent on mechanical loading conditions in the heart.
However, PE has also been shown to act directly on cardiac myocytes by inducing
myocyte hypertrophy [Clerk et al. 1998]. Therefore, while PE isn’t the best choice for
regulating afterload, nevertheless these results are interesting. Finally, doses of sunitinib
exceeding 40 mg/kg per day have been shown to induce LV dysfunction [Khakoo et al.
2013]. The authors observed decreases in EF as well as contractile reserve. Additionally,
hearts treated with sunitinib suffered greater dysfunction after undergoing TAC (transaortic constriction), an intervention that greatly increases the amount of afterload
experienced by the heart (referred to as “pressure overload”) [Khakoo et al. 2007]. Again,
we see signs that sunitinib toxicity may be regulated by afterload. Like PE administration,
TAC has its disadvantages as a method for increasing afterload because it is pathologic
independent of sunitinib treatment. In Chapter 5, we will discuss how we can use our
microtissue platform to assess the contribution of afterload to sunitinib cardiotoxicity.
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2.2.1.3 Results from Primary Rat Cell Culture Studies
In studies that utilized doses of sunitinib around 0.1-10µM, cytochrome-C and
caspase 3/7 activation were observed indicating rapid apoptosis of neonatal rat cardiac
myocytes. Maayah and colleagues report decreases in cell viability of 35%, 50%, and
70% in cultures treated with 25µM, 50µM, and 100µM sunitinib respectively [Maayah et
al. 2014]. There were also reported decreases in ATP levels as well as mitochondria
membrane potential [Maayah et al. 2014]. The effect on cell energetics prompted Kerkela
and colleagues to investigate dysregulation of AMPK (5' AMP-activated protein kinase)
as the culprit. In general, AMPK is activated during times of energy depletion and helps
maintain ATP levels by restricting energy utilization and increasing energy production.
Kerkela et al. discovered that sunitinib can directly inhibit the activity of AMPK (i.e.
phosphorylation of acetyl CoA carboxylase, p-ACC). This could contribute to decreased
ATP levels in cardiac myocytes treated with sunitinib [Kerkela et al. 2009].
In addition to affecting viability and energetics, changes in myocyte function were
associated with sunitinib treatment. Rainer and colleagues reported that 1.87µM sunitinib
was sufficient to negatively affect sarcomere shortening and reduce calcium transients in
isolated adult rat cells [Rainer et al. 2012]. As a whole these studies suggest that sunitinib
negatively affects cardiomyocyte energetics via inhibition of AMPK, viability, and
function. However many studies were performed using sunitinib levels outside the range
of concentrations that are clinically relevant.

25

2.2.1.4 Results from Human Muscle Strip Study
In addition to examining sunitinib toxicity in single adult mouse myocytes, Rainer
and colleagues also assessed toxicity in muscle strips from the right atrium of patients.
This part of their study stands out because it’s the only set of in vitro experiments
utilizing adult human heart tissue. Muscle strips are difficult to obtain and have very high
metabolic demands and unfortunately most experiments can only last for 24hr before
muscle strips fail. Hence muscle strips do not serve as strong pre-clinical model for drug
toxicity. Nevertheless, this study serves as model of relevant human biology and its
results guided the design of our own functional experiments in rat cells. Less than 30 min
of treatment with 1.87µM and 18.7µM sunitinib was sufficient to affect active force
generation (decreased by 8% and 15% respectively) by muscle strips with no effect on
diastolic forces. This finding helps to validate observations of LV dysfunction in human
patients treated with sunitinib. [Rainer et al. 2012]

2.2.1.5 Summary and Study Limitations
In summary, the literature provides evidence that sunitinib can lead to LV
dysfunction and cellular apoptosis, as well as depletion of ATP stores and mitochondrial
dysfunction. However, the results presented here are highly dependent on the dose and
duration of sunitinib treatment. There exists a need for more studies aimed specifically at
characterizing the effects of sunitinib dose and duration on cardiotoxicity. Additionally,
animal studies reveal a possible contribution of afterload to sunitinib cardiotoxicity,
however better methods for controlling afterload are needed as current methods, such as
PE and TAC, can have off-target effects on myocytes. Finally, there is only a single study
examining sunitinib cardiotoxicity in isolated human tissues. Moreover, this study is
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limited by the use of atrial (rather than ventricular) tissue and by relatively high doses of
sunitinib treatment. This thesis will aim to address both of these shortcomings in the
literature.

2.3 Utilizing Human Pluripotent Derived Cardiomyocytes and Tissue
Engineering Methods as Models for Detecting Sunitinib Induced
Cardiotoxicity

2.3.1 Establishing Standardized, Relevant Screening Methods for Predicting
Cardiotoxicity
The previous sections have revealed significant shortcomings in our 1) ability to
predict or identify sunitinib induced cardiotoxicity its early stages and 2) biologic
understanding of mechanisms behind sunitinib’s cardiotoxic effects. Current preclinical
models are not well equipped to address these concerns [Astashkina et al. 2012]. CHO
cells transfected with hERG channels are poor reductionist models of cardiac myocytes
due to the lack of any contractile apparatus and complex ion channel network [FDA
CDER 2005]. Animal models suffer from interspecies differences in cardiac biology,
which are well documented and cannot be ignored [Seok et al 2013; Houser et al. 2012].
Developing robust preclinical models of sunitinib cardiotoxicity would allow us to begin
addressing both issues. A good preclinical model would: 1) utilize human cell inputs; 2)
permit control over cellular, biochemical, extracellular matrix (ECM), and mechanical
cues and 3) provide functional readouts that can be used as metrics for toxicity. This
section will outline how we can derive suitable human cardiac cell sources and utilize
current tissue engineering methods as an in vitro testing platform.
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2.3.2 The Rise of Human Cardiac Cell Sources from Pluripotent Stem Cells
2.3.2.1 Advances in Cardiac Differentiation from Human Pluripotent Stem Cells
Given the complexity of the human heart, differentiating human pluripotent stem
cells (hPSCs), such as induced pluripotent (iPS) or embryonic stem (ES) cells, into
cardiac cell types presented major challenges for researchers (see Figure 2.6 for an
overview). Cardiac development is a complex interplay of various signaling pathways
that are activated at specific time points during development [LaFlamme et al. 2011].
Researchers Gordon Keller and Charles E. Murry were among the first integrate this idea
into their research. They identified Bone Morphogenic proteins (BMPs), specifically
BMP-4, and Activin-A (nodal TGF-Beta pathway) as pivotal molecules for mesoderm
determination, a critical step in cardiogenesis. [Kattman et al. 2011; Lian et al. 2013]

Figure 2.6: Complexity of Cardiac Differentiation during development. Various
signaling pathways involved in the differentiation of pluripotent stem cells to cardiac
myocytes. [Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer
Research UK: Nature, Michael A LaFlamme and Charles E Murry, “Heart Regeneration”
Vol. 473 Issue 7347, Copyright 2011: License no. 3984420749070]
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Murry and Keller’s differentiation protocols often times called for numerous
growth factors supplemented in expensive basal media such as StemPro®. Thus their
differentiation strategies were not cost-effective when it came to scaling up production of
hPS-CMs [Kattman et al. 2011]. The Wu lab at Stanford developed a more cost effective
strategy for creating a chemically defined media that produced highly pure (>80%)
cultures of human cardiomyocytes that is increasingly used today. The protocol calls for
fewer growth factors, as well as a more cost effective basal media (RPMI 1640).
Furthermore, this differentiation protocol was successful on a number of iPS cell lines,
despite genetic differences between the cell lines. Many of the human experiments
conducted in this work utilized this differentiation method and will be discussed in more
detail in later sections. [Burridge et al. 2014]

2.3.2.1 Differences Between hPS-CMs and Adult Human Cardiomyocytes
To utilize hPS-CMs for drug screening, ideally we would like these cells to
exhibit a phenotype resembling that of an adult cardiomyocyte. However, despite
advances in CM differentiation and maturation methods, hPS-CMs do not exhibit many of
the characteristics of an adult myocyte. These cardiomyocytes are postulated to behave
more like fetal cardiomyocytes. Yang et al. highlighted many of these differences in a
recent review article; and the many differences are highlighted below (Table 2-2). [Yang
et al. 2014]
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Table 2-2: Differences between adult cardiomyocytes and hPS-CMs. Immature
Cardiomyocytes, such as hPS-CMs, do not display the same behaviors as adult human
cardiomyocytes. [Adapted by permission from Wolters Kluwer: Circulation Research,
Xiulan Yang, Lil Pabon, Charles E. Murry, “Engineering Adolescence” Vol. 114 Issue 3,
Copyright 2014: License no. 3984421278291]

While there are various differences amongst fetal and human cardiomyocytes,
hPS-CMs still hold great potential for studying human cardiac diseases and for drug
screening. However, investigators must realize that certain biological questions are not
suitable to answer with hPS-CMs because they don’t exhibit that particular adult
phenotype. Some examples include: changes in metabolism with heart failure and
studying inotropic responses; this also must be kept in mind for determining metrics for
drug induced cardiotoxicity. However, hPS-CMs remain useful to for determining
whether a drug is intrinsically toxic (i.e. induces apoptosis, necrosis) [Burridge et al 2016;
Clements et al. 2015; Gilchrist et al 2015]. It is for that reason we sought to continue to
utilize hPS-CMs in some of our experiments presented in Chapter 6.
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2.3.2.2 Creating Patient-Specific hPS-CMs for Predictive Toxicology
hPS-CMs not only serve as a reliable human cardiac cell source, they also have
the potential to allow for an “individualized medicine” approach to predict cardiotoxicity,
specifically, creating patient-specific hPS-CMs and screening them with compounds to
help predict cardiotoxic responses. This is especially useful for patients with a known
genetic mutation. We can re-program their somatic cells into an iPS cell line, differentiate
these cells into hPS-CMs, and study their responses in vitro (Figure 2.7 panel A).
Carvajal-Vergara and colleagues were able to create hPS-CMs with patients with
LEOPARD syndrome, a mutation in the Ras-MAPK pathway, which is known to cause
hypertrophic cardiomyopathy. The authors compared wild-type to LEOPARD hPS-CMs
and found that the latter cell type had characteristics of hypertrophy such as increased cell
size and increased NFAT4 (Nuclear factor of activated T-cells 4) localization to the
nucleus [Carvajal-Vergara et al. 2010]. In a separate study, Hinson and colleagues
examined the role of Titin mutations with hPS-CMs derived with patients with a specific
mutation. They found that the cells with the mutation exhibited lower twitch force
compared to wild-type hPS-CMs [Hinson et al. 2015]. Thus the ability to create hPS-CMs
from patients with an altered genetic background can provide helpful insights into
consequences of certain mutations on cardiomyocyte function. This idea can be extended
to include studying how certain mutations will affect how a patient responds to a certain
drug.
In addition to creating hPS-CMs from patients with altered genetic backgrounds,
we have also gained the ability to genetically edit iPS cells using newly developed Cas9
technology and create hPS-CMs from these cells [Musunuru 2013; Strong et al. 2017].
Genome editing allows us to either create new mutations or correct existing mutations and
examine phenotypic responses (Figure 2.7 panel B). [Musunuru 2013]
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Figure 2.7: Comparison of two methods for disease modeling using hPS-CMs. A)
Reprograming somatic cells from healthy and diseased patients into iPSCs and
differentiating them into hPS-CMs. B) Genome editing of wildtype iPS or iPS with
mutation to correct or mutate genes. [Figure adapted under the terms of the Creative
Commons Attribution License: Disease Models & Mechanisms, Kiran Musunuru,
“Genome editing of human pluripotent stem cells to generate human cellular disease
models.” Vol 6: pgs. 896-904: Copyright 2013]

Therefore, we can compare two cell lines that are genetically identical except for
the presence or absence of a mutation. Hinson and colleagues also performed such
experiments in their study; they created multiple iPS cell lines with different Titin
mutations. They found that different mutations led to varying degrees of decreased force
generation by cardiomyocytes created from these lines [Hinson et al. 2015]. Similar to
creating iPS cells using patients with a genetic background, genome editing is a valuable
tool for gaining insights into functional consequences of mutations and has the potential
to provide us with more “informed” pre-clinical models for drug testing.
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2.3.2.3 Studying Sunitinib Toxicology using hPS-CMs
A limited number of studies have begun assessing the cardiotoxicity of sunitinib
using hPS-CMs. Many of these studies utilized a commercially available hPS-CM source
manufactured by Cellular Dynamics Inc. In one study Cohen and colleagues found that
31µM sunitinib completely depleted ATP levels, and induced LDH release and caspase
activation [Cohen et al. 2011]. In a separate study, Doherty and colleagues found that as
little as 625nM sunitinib can cause disruptions in normalized beating rate, and 10µM
sunitinib leads to a complete arrest of beating [Doherty et al. 2013]. Some major
limitations with these studies are: 1) the use of non-physiological concentrations of
sunitinib, specifically in the Cohen study; 2) no assessment of effect of afterload on
toxicity; and 3) experiments were performed in flat, 2D cultures. Regarding the latter,
culturing cells on rigid, flat substrates is clearly structurally and mechanically nonphysiologic. 2D culture is known to cause morphologic changes such as distortions of
sarcomere organization and impose a non-physiologic amount of preload and afterload on
cells, which will inherently negatively affect their function [Soares et al. 2012]. In the
next section, we will go over alternate methods for culturing cells using current tissue
engineering methods, and argue that these tissue culture models serve as better platforms
for pre-clinical drug screening on cells such as hPS-CMs.
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2.3.3 Utilizing Tissue Engineering Models as Cell Culture Platforms for Drug Screening
2.3.3.1 Design Criteria for Tissue Culture Models and Limitations with Conventional
Methods
Even with the right type of cells, a suitable tissue culture platform is a necessity
for improving current drug screening methods. An ideal platform would permit control
over cellular, biochemical, and mechanical inputs so we can assess the relative
contributions of each parameter [Ma et al. 2016; Ogle et al. 2016; Zhao et al. 2016].
Additionally, the platform would allow for making multiple measurements of tissue
function. In the case of screening for cardiotoxicity, some examples of important
functional assessments would include force generation and action potential peaks and
kinetics. Current tissue culture platforms such as 2D flat cultures and animal models are
inherently limited in their ability to control one of more of the design criteria listed above,
and 2D culture platforms in particular are limited in their ability to provide functional
data, such as force generation. Advances in the field of cardiac tissue engineering have
resulted in improved strategies that combine the advantages of 2D in vitro culture and
animal models to create a platform that fits the design criteria above. In this section we
will outline some of these advances and discuss how they can be utilized for improving
drug screening.

2.3.3.2 Engineered Tissues Display Hallmarks of Cardiac Physiology
Engineered tissues consist of cells combined with some kind of natural or
synthetic ECM that are seeded on millimeter scale or micron scale platforms. For
example, cells can self-assemble on a set of pillars/cantilevers or have their adhesion
guided by engineering material properties (micropatterning, 3D printing, etc.) to control
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cellular alignment (Figure 2.8). [Cashman TJ et al. 2016; Boudou et al. 2012; Lind et al.
2016]

Figure 2.8: Generating Engineered Cardiac Tissue. A) Human engineered heart tissue
formed between two pillars. [Adapted by permission from Creative Commons Attribution
license; Original Article: Cashman TJ et al. “Human Engineered Cardiac Tissue Using
Induced Pluripotent Stem Cells Reveal Functional Characteristics of BRAF-mediated
Hypertrophic Cardiomyopathy.” PLOS One 2016; 11:e0146697.] B) Microgrooves guide
cardiomyocyte alignment using topographical features. [Reprinted by permission from
Macmillan Publishers Ltd: Nature Materials, Johan U. Lind, Travis A. Busbee, Alexander
D. Valentine, Francesco S. Pasqualini, Hongyan Yuan, Moran Yadid, “Instrumented
cardiac microphysiological devices via multi-material three-dimensional printing”
Advance Online Publication, Copyright 2016: License no. 3984441121068]

Engineered tissues can be electrically stimulated to give readouts of force and
action potential waveforms (Figure 2.9 panels A, D). These tissues can also respond
appropriately to the calcium blocker verapamil and beta-adrenergic agonist isoproterenol
(Figure 2.9 panel B) [Lind et al. 2016]. Additionally, various authors have argued that the
cells themselves can mature within these platforms [Tiburcy et al 2011]. Figure 2.9 (panel
C) demonstrates how NRCMs can adopt a more adult-like morphology when being
cultured in engineered heart tissue (EHT).
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Figure 2.9: Engineered Tissues Recapitulate Aspects of Cardiac Physiology. A)
Neonatal rat cardiomyocytes in engineered tissues decrease their generated stresses (yaxis on plots) in response to increasing concentrations of the calcium channel blocker
verapamil. B) Similarly, hPS-CMs respond to the β-adrenergic agonist isoproterenol by
augmenting developed stresses. [Reprinted by permission from Macmillan Publishers
Ltd: Nature Materials, Johan U. Lind, Travis A. Busbee, Alexander D. Valentine,
Francesco S. Pasqualini, Hongyan Yuan, Moran Yadid, “Instrumented cardiac
microphysiological devices via multimaterial three-dimensional printing” Advance
Online Publication, Copyright 2016: License no. 3984441121068]. C) NVRMs cultured
in EHTs undergo advanced maturation, adopting morphologies resembling the adult
phenotype. [Adapted by permission from Wolters Kluwer: Circulation Research, Malte
Tiburcy et. al “Terminal Differentiation, Advanced Organotypic Maturation, and
Modeling of Hypertrophic Growth in Engineered Heart Tissue” Vol. 109 Issue 10,
Copyright 2011: License no. 3984450925448]. D) Action Potentials generated by EHTs
composed of hES-CMs. [Figure adapted under Creative Commons Attribution license:
PLOS ONE, Sebastian Shaaf et. al, “Human Engineered Heart Tissue as a Versatile Tool
in Basic Research and Preclinical Toxicology” 2011.
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2.3.3.3 Using Engineered Tissues to Study the Contribution of Cellular, Biochemical, and
Mechanical Microenvironments on Tissue Function
One major design criterion highlighted above was that an ideal drug screening
platform should permit control over cellular, biochemical, and mechanical inputs.
Understanding how a cell’s response to a drug is influenced by these factors will
important for maximizing the effectiveness and safety of new candidate drugs [Ma et al.
2016]. Many engineered tissue models permit control over one or more of the factors
listed. This section will discuss some of these attributes and explain their importance.
2.3.3.3.1 Cellular Inputs
Heart tissue is not just composed of cardiac myocytes; there are also nonmyocytes such as fibroblasts and vascular cells (endothelial and smooth muscle)
present. Previous works have demonstrated the important role these non-myocytes
play in maintaining cardiac homeostasis [Tian et al. 2012]. Hence, tissue
engineers must decide what non-CM cell types to incorporate and at what ratio.
Early work with EHT utilizing neonatal rat heart isolations found that tissues
made from the “native” mix of heart cells generated higher diastolic and systolic
forces and were more sensitive to calcium compared to EHTs composed of CM
enriched cultures [Naito et al. 2006]. In a separate study using neonatal rat cells,
Radisic and colleagues found that not only the presence of fibroblasts impacted
tissue function, but also the order in which cells are seeded [Radisic et al. 2008].
The authors found that pre-seeding tissues with fibroblasts and seeding CMs later
created tissues with better tissue shortening (analogous to force generation), better
elongation of CMs, and more electrical sensitivity. In a study utilizing human ESCMs, Zhang and colleagues found that within the range of 45%-90% CMs, the
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active force generated per CM actually decreased as purity increased, suggesting
that the non-myocyte fraction played an important role in hES-CM maturation
within tissues [Zhang et al. 2013]. In summary, cellular factors are important
determinates of tissue function, with non-myocytes being key players that should
be included in engineered tissues.

2.3.3.3.2 Biochemical Inputs
Biochemical inputs clearly modulate cardiac structure and function. An advantage
of in vitro systems is the ability to selectively adjust these inputs. In contrast,
animal models suffer from a relative lack of control over biochemical factors.
Specifically, the target tissue will also be influenced by factors secreted by other
organ systems, which could confound results. The in vitro nature of engineered
tissues allows the user to control biochemical factors introduced to the tissue
through the addition of culture medium. Many researchers are even switching
from serum containing medium to serum-free, chemically defined medium in
order to better assess the effects of different chemical factors. In one study
utilizing EHT, the authors found that neonatal rat EHTs grown in serum-free
media without any growth factor supplementation did not produce active
contractions. Growth factors such as IGF-1, EGF, bFGF, endothelin-1,
angiotensin II, cardiotrophin-1, and TGFB-1 were crucial for active force
generation [Naito et al 2006]. Thus, biochemical factors play a major role in tissue
function and may affect responses to drug compounds.
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2.3.3.3.3 Mechanical Factors
Mechanical stimulation is especially important when trying to model cardiac
tissue, as cardiac cells are constantly exposed to some degree of mechanical
loading during all stages of the cardiac cycle. Therefore any engineered tissues
should aim to include some degree of mechanical loading. In models where cells
self-assemble on flexible cantilevers, tissues are allowed to undergo shortening
isotonic contractions, which corresponds with the in vivo heart [Boudou et al.
2012]. This setup would be favorable for daily maintenance of tissues. However,
for assessment of contractile performance, it would be ideal to have the tissue
contract at a fixed length or adjustable lengths because resting tissue length has a
profound effect on active force generation [Brady et al. 1991]. Early EHT models
also incorporated cyclic strain as a source of mechanical loading [Zimmermann et
al. 2000]. While the heart does beat cyclically, the application of cyclic strain may
lead to lengthening contractions (tissue elongated during contraction). Such
contractions, termed eccentric contractions, have been shown to induce cellular
apoptosis in muscle strip models [Liaoa et al 2003]. Thus the application of cyclic
strain to engineered tissues may not be well suited for inquiries focused on in vitro
toxicity.
One mechanical parameter particularly relevant to sunitinib cardiotoxicity is
afterload. In models where tissues develop on cantilevers, the “spring constant” of
the cantilever serves as the major determinate of afterload. The spring constant
will be a function of the cantilever geometry and material properties. In some
EHT experiments, the authors reinforced their silicone posts with metal braces
during culture to make them completely rigid [Hirt et al. 2012]. They found that
this increase in afterload increased expression of hypertrophic genes such as ANP
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(atrial naturetic peptide) and BNP (brain naturetic peptide), increased tissues cross
sectional area, and increased glucose consumption [Hirt et al. 2012]. The authors
did not look into long term effects on generated force to see if force generation
would ultimately decline in response to the chronic afterload increase.
Additionally, making the rods completely rigid represents a non-physiologic
increase in afterload, which hurts the relevance of their findings. Chapter 5 of this
thesis will be aimed at examining how sunitinib’s toxicity is influenced by the
degree of afterload.
Along those lines, another important class of mechanical forces to consider are
electro-mechanical forces, specifically field stimulating engineered tissues. The
Radisic Lab has helped elucidate the role of electrical stimulation on the
maturation of engineered cardiac tissues for the past decade. In one of their
earliest works using neonatal rat engineered tissues, they reported that continuous
stimulation (pulse: rectangular, 5V/cm, 2ms duration, 1Hz) led to a high degree of
ultrastructural organization within tissues, where cardiomyocytes would align in
the direction of electrical stimulation [Radisic et al. 2004]. In more recent work
utilizing hPS-CMs (cardiac microwires), they report that continuous stimulation
increased gene expression of developmental genes (myosin light chains BNP) and
increased conduction velocities so that are within the range of healthy adult
human hearts [Thavandirana et al. 2015]. Thus, electrical stimulation represents
another important factor to consider incorporating into an engineered tissue
model.
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2.3.4 Concluding Remarks
Advances in human pluripotent stem cell technology and bioengineering have the
potential for creating robust human cardiac tissue models that allow for user-control over
cellular, biochemical, and mechanical inputs, all of which have been shown to influence
cell function. It’s important to start considering these factors earlier on in drug
development to create drugs that are safer and more effective. Future advances in high
throughput screening of such tissues would make them a very attractive model system to
adopt in pharmaceutical industry.
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Chapter 3: Experimental Methods and Procedures
3.1 Cell Culture Maintenance and Derivation
3.1.1 Primary Culture of Neonatal Rat Cardiomyocytes (NRCMs)
NRCMs were isolated from day 0-1 Sprague Dawley rat pups. Pups were
decapitated and a median sternotomy was immediately performed to excise hearts. Hearts
were placed in fresh cold Hanks Balanced Salt Solution (HBSS; Gibco, Life
Technologies, cat no 14170-112 ) with 1% Penicillin/Streptomycin/Glutamine (P/S/G;
Gibco, cat no 10378-016), trimmed free of atria and other blood vessels, and put in fresh
HBSS+P/S/G. Hearts were minced in a 6-well plate with ethanol-cleaned scissors and
washed twice in fresh HBSS+P/S/G. Minced hearts were incubated with 10mL of trypsin
(Worthington Biochemical, cat no LS003703) solution (0.1%-0.2% trypsin in
HBSS+1%P/S/G) for 15min at 37⁰C. The resulting supernatant solution consisting of red
blood cells and debris was removed and 10ml of fresh trypsin solution was added.
Solution was incubated for 15 min at 37⁰C while shaking at 200 rpm. The supernatant
was discarded again, 10ml of trypsin solution was added, and the preparation was
incubated for an additional 15 min at 37⁰C with shaking. This time the supernatant was
collected and filtered through a 70µm nylon mesh filter (Beckman Dickinson, cat no.
352350) into a 50ml conical tube containing 10ml of ice cold culture media consisting of
10% Horse Serum (Gibco, cat no 26050-088), 5% Fetal Bovine Serum (Hyclone, cat no
SH30071.03), 10mM HEPES (Gibco, cat no 1563-0080), 1% P/S/G in 3:1 ratio of
Dulbecco’s Modified Eagle Medium (DMEM; Gibco cat no 11965-084) and Medium 199
(M199 1x; Gibco cat no 11043-023) on ice to stop trypsin reaction. The remaining pellet
was subjected to additional rounds of trypsin digestion to release more cells. Released
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cells were collected by centrifuging filtered permeate at 80xg for 5min at 4⁰C (brake off).
Cells were plated on tissue culture plastic for 1hr at 37⁰C and 5% CO2 and supernatant
was collected to enrich for cardiomyocytes. This CM enriched fraction was plated on
fibronectin (Sigma Aldrich, cat no. F1141) coated dishes overnight. These cells were used
the next day for microtissue seeding.
3.1.2 Human Pluripotent Stem Cell Culture and Cardiac Differentiation
The human iPS cell line SV20 was kindly provided by iPS Core lab of Penn
Cardiovascular Institute (http://web.expasy.org/cellosaurus/CVCL_EL23).
Undifferentiated colonies were maintained on Matrigel ™(Beckman Dickinson, cat no.
35427) coated plates (0.5mg Matrigel ™per 6 -well plate) in mTESR ™medium (Stem
Cell Technologies, cat no. 05850) at 37⁰C, 5% CO2, and 21% O2. Colonies were
passaged every 3-5 days using accutase (Sigma Aldrich, cat no A6964).
For cardiac differentiation, iPS cells were allowed to grow for 4 days or until they
reach ~75% confluency.


Day -2: Cells were dissociated with accutase and re-plated in Matrigel ™coated
12-well plates (2mg per 12-well plate) at a density of 106cells/well in mTeSR
media supplemented with 5µM Rock Inhibitor (Y27632; Enzo, cat no ALX-270333-M005) overnight.



Day 0: Media was switched to RPMI 1640 (Gibco, cat no11875-085) + B27
supplement (minus insulin; Gibco, cat no A1895601) +1µM Chiron 99021 (LC
Laboratories, cat no. C-6556)
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Day 2: Media wasswitched to RPMI 1640 + B27 supplement (minus insulin) +
2µM Wnt-C59 (Tocris Bioscience, cat no. 5148)



Day 4: Media was switched to RPMI+ B27 (minus insulin).



Day 6: Media was switched to RPMI +B27 (plus insulin; Gibco, cat no 17504044).

From this point on, cells were maintained in RPMI+B27 (plus insulin) media. Initial
beating was observed starting at day 7-12. Metabolic selection (glucose starving) was
performed to enrich for cardiac lineages after day 10. In brief, media was exchanged to
RPMI (without glucose; Gibco, cat no 11879-020) +5mM sodium DL-lactate (Sigma
Aldrich cat no L4263) for 6-10 days with media changes every 2 days. Cells were given
several days to recover after metabolic selection before performing any experiments.
After metabolic selection, CM purity was in the range of 80-90%.
3.1.3 Human Mesenchymal Stem Cell Culture
Human Mesenchymal Stem Cells (hMSCs) were purchased from Lonza. hMSCs
were maintained in alpha MEM media (Gibco, cat no 12561-056) supplemented with
2mM (1%) Glutamax (Gibco, cat no 3505-061), and 100U/mL Penicillin / Streptomycin
solution (P/S; Gibco, cat no. 15141-122). Cells were passaged every 3-4 days with 0.05%
Trypsin EDTA (Gibco, cat no. 25300-054) up until passage 10 where cells became
senescent. Cells from passages 7-10 were used for experiments involving human CMTs to
minimize hMSC proliferation within microtissues.
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3.2 Fabrication of µTUG Arrays

3.2.1 Microfabrication of Silicon Masters
Multilayer templates were created by photo-patterning SU-8 (all from Microchem)
photoresist onto silicon wafers (Single-sided polished, Prime grade) using successive spin
coats (CEE 200X, Brewer Science, Inc.), alignment (AMB 3000 HR Mask Aligner, AMB
Inc.) and UV exposure (360nm), and baking steps. Figure 9 details this process. The base
cantilever structure was created by spin coating SU8 2002 to create ~2.4µm layer and
exposing this layer to 100mJ of UV (Figure 9, Step 2). To fill in the interstitial layer (the
well), SU8 2100 was spin coated to create a ~200µm layer, followed by spin coating SU8
2010 + 30% S1813 to create a small ~2.4µm layer, and finally, exposing a bottom layer
photomask to 700mJ of UV (Figure 9, Steps 3-4). The top lithography was created by
spin coating SU8 2050 to create another thin ~2.4µm layer and exposing a top layer
photomask to 95mJ of UV (Figure 9, Steps 5-6). These masters were then developed in a
single step in SU-8 developer (Microchem) which was stopped by submersion in
isopropyl alcohol (IPA, Sigma cat no I9516), followed by a hard bake (Figure 3.1, Step
7).
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Figure 3.1: Fabrication of Silicon Masters with Soft Lithography. Templates were
created by photo-patterning SU-8 photoresist onto wafers using successive spin coat,
alignment and UV exposure, and baking steps. Figure Credit: Elise A. Corbin, PhD.
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3.2.2 Fabricating µTUG arrays from Silicon Masters
“Stamps” (negatives of silicon wafer), were cast by pouring a pre-polymer (10:1
base to curing agent ratio) of poly-dimethyl siloxane (PDMS, Sylgard 184; Dow Corning,
cat no 2120925) onto wafers, degassing molds, baking overnight at 60⁰C, and peeling off
with ethanol. These stamps could then be used multiple times to generate µTUG arrays.
Stamps were plasma cleaned under air for 1 min on high using a Harrick expanded
plasma cleaner (Sigma Aldrich, cat no Z561657) and silanized with trichloro -(1H, 1H,
2H, 2H-perfluorooctyl) silane (Sigma Aldrich, cat no 448931) under vacuum overnight.
For active force measurements, fluorescent beads (Fluoresbrite® YG Carboxylate
Microspheres 3.00µm; Polysciences, Inc.) diluted 1:3000 in ethanol were centrifuged into
silanized stamps to embed beads in final device. PDMS pre-polymer (5:1 to 15:1 base to
curing agent ratio) was then poured onto silanized stamps and stamps were then inverted
onto a hardened layer of PDMS in a 35 mm dish (Corning, cat no 430165). These
substrates were baked at 60⁰C for 24hr. Stamps were removed from the molds carefully
using ethanol as a lubricant to avoid damaging tops of cantilevers. Molds were washed in
IPA and dried before seeding cells.
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3.3 Preparation of Cardiac Microtissues

3.3.1 Neonatal Rat Cardiac Microtissue Seeding Procedure
Neonatal rat microtissues were prepared in the same manner as described in
Boudou et al. 2012 with a few exceptions. Figure 3.2 (panel A) gives an overview of the
microtissue seeding process. Briefly, µTUG arrays were sterilized with 70% ethanol and
left to dry for 30min (Figure 3.2 panel A Step 1-2). To prevent cell attachment against the
walls of the wells, the molds were treated with 0.02% w/v Pluronic F127 (Sigma Aldrich,
cat no P2443) for 3hr (Figure 3.2 panel A Step 3) on the surface and 30min inside the
wells by centrifuging pluronics solution at 1600xg for 2min (Figure 3.2 panel A Step 4).
Pluronics were washed out with Dulbecco’s Phosphate Buffered Saline solution (DPBS
no Ca++/Mg++; Gibco cat no 14040-117) followed by dH2O (Figure 3.2 panel A Step 5). At
this time, NRCMs were detached from tissue culture plates with 0.05% Trypsin EDTA
for 4 min. 106- 1.2x106 NRCMs were used to seed each array. A Collagen I gel (rat tail;
Corning, cat no. 354236) was used as an ECM in which to create microtissues. A liquid
neutralized collagen I solution (1 mg/ml) was created by mixing collagen I, fibrinogen
(0.5 mg/mL final concentration; Sigma Aldrich, cat no F8630), HEPES (10mM final
conc.), NaHCO3 (4.17mM final conc.; Sigma cat no S5761), 1M NaOH (neutralization
ratio: 0.5; Sigma, cat no S8045), M199 (10x) (1x final conc.; Sigma Aldrich, cat no.
M0650) in sterile dH2O on ice. A base layer of collagen (1ml per array) was added and
degassed to pull collagen into the wells (Figure 3.2 panel A Step 6). Cells were then resuspended into collagen solution, added to arrays, and centrifuged twice at 350xg for 90
seconds (arrays rotated 90 degrees in between spins) (Figure 3.2 panel A Step 7-8).
Excess collagen in between wells was removed using a vacuum aspirator (Figure 3.2
panel A Step 9). Arrays were inverted and centrifuged at 50xg for 17 seconds to move
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cells down the pillars. Collagen was polymerized inside an incubator at 37⁰C, 5%CO2,
21% O2 for 15min (Figure 3.2 panel A Step 10). Culture media consisting of DMEM high
glucose + 10% Horse Serum + 2% Chicken Embryo Extract (Charles River Laboratories,
cat no 10100330) + 1% Antibiotic/Anti-mycotic solution (Gibco, cat no 15420-062) was
added to arrays and arrays were put back into the incubator (Figure 3.2 panel A Step 11).
Cells compacted ECM and tissues formed over the course of 24hr (Figure 3.2 panel B).

Figure 3.2: Constructing Cardiac Microtissues. A) Process flow diagram for
microtissue seeding procedure on 120 well arrays. B) Cells self-assemble and compact
collagen matrix over 24hr to create a tissue bound to pillars. Figure adapted from: Legant
WR, Pathak A, Yang MT, et al. “Microfabricated tissue gauges to measure and
manipulate forces from 3D microtissues”. PNAS. 2009; 106:10097-10102; Copyright
2009 National Academy of Sciences.
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3.3.2 Human Cardiac Microtissue Seeding Procedure
Human CMTs were prepared in the same manner as rat CMTs with a few
exceptions: arrays were treated with 0.1% Pluronic F127 to allow for tissue release from
the sides of the well. Monolayers of beating iPS-CMs (day 16-day 30) were detached
from culture plates using TrypLE Express (Gibco, cat no 12605-010) for 7-10min at
37⁰C/5%CO2. Human MSCs were detached from culture plates with 0.05% Trypsin
EDTA for 5min at 37⁰C/5%CO2. iPS-CMs and hMSCs were mixed to create tissues
composed of 93% CMs /7% hMSCs. Tissues were maintained in RPMI+ 20%
FBS+100U/mL P/S+ 5µM Y27632 media for the first 24hr and then switched to RPMI +
B27 (plus insulin) + 1% P/S media, which was exchanged every 2 days. Beating would
often times not be visible during the first 2 days in culture.

3.4 Drug Studies
Stock solutions (10mM) of Sunitinib malate (LC Laboratories, cat no S-8803)
were prepared in DMSO (Life Technologies, cat no.D12345) and were re-made every 6
months to ensure biological activity. Stock solutions were diluted at least 1:1000 in media
for experiments to avoid any DMSO induced toxicity. Samples treated with DMSO at the
same %v/v were used as controls (vehicle). Microtissues treated with 1µM Staurosporine
(Sigma Aldrich, cat no S6942) were used as a positive control for apoptosis. Carbonyl
cyanide m-chlorophenyl hydrazone (CCCP; Sigma Aldrich, cat no C2759) was used a
positive control for mitochondrial membrane potential disruption at a concentration of
50µM and was incubated with cells for 30min. In a subset of experiments, 5Aminoimidazole-4-carboxamide 1-β-D-ribofuranoside, Acadesine (AICAR; Sigma
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Aldrich, cat no A9978) was administered concurrently with sunitinib at a concentration of
1mM.

3.5 Analytical Methods
3.5.1 Detecting Cell Death in Cardiac Microtissues
3.5.1.1 Measuring Apoptosis via Caspase 3/7 Activation
One of our primary metrics for assessing cardiotoxicity in CMTs is the effect of
sunitinib on cell viability, and specifically the induction of apoptosis. Caspase activation
is one of the earliest signals of apoptosis in cells and involves the proteolytic cleavage of
pro-caspase molecules into activated caspase molecules that either activate other caspases
(initiator caspases) or are directly involved in carrying out apoptosis (executioner).
Caspases 3 and 7 are executioner caspases expressed in nearly all tissues, and were a key
readout for toxicity in most experiments. Because caspases are activated posttranslationally, the assay we choose must be able to selectively label the active form of
the caspase. Additionally, because our microtissues only contain roughly 500 cells per
tissue, we also need to utilize an assay that is sensitive enough to get a signal from only a
few thousand cells. In light of this observation, we decided to proceed with a
luminescence based assay as they tend to be more sensitive than calorimetric ones.
Specifically we chose to utilize the Caspase-Glo® 3/7 assay (Promega Corporation, cat
no PRG8090). The Caspase-Glo® assay contains a 2-part reagent consisting of 1) a cell
lysis buffer and 2) a DEVD tetrapeptide conjugated to a luminogenic substrate. Upon cell
lysis, activated caspases 3 and 7 will cleave the DEVD peptide, releasing the luminogenic
substrate allowing it to react with luciferase and produce light that can be quantified
(Figure 3.3 panel A).
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Initial experiments with the Caspase-Glo® assay suffered from background
issues, most likely from the serum-containing media that CMTs are cultured in. Although
the assay is supposedly compatible with serum containing culture media, our observations
suggested otherwise after comparing signal-to-noise ratios for samples in a) serum
containing media, b) DPBS with residual media (~10%), or c) samples washed
thoroughly in DPBS. The results shown in Figure 3.3 (panel B) demonstrate the
importance of removing any residual media in order to maximize signal-to-noise ratios.

Figure 3.3: Measuring Activated Caspase 3/7 in CMTs with Caspase-Glo®3/7.
A) Cleavage of luminogenic substrate containing DEVD sequence by activated caspases
induces luciferase rxn. Picture used with permission from Promega Corporation. B)
Signal-to-noise ratios for samples treated with either 1% DMSO or 1µM sunitinib in
various media. C) Testing the linear region of Caspase-Glo® assay using cells treated
with 0.1% DMSO (blue line) or 1µM Staurosporine (red line); n=3 technical replicates.

52

We also took care to identify the linear operating range of this assay that was
estimated by the manufacturer to be 50-20,000 cells. This allowed us to accurately report
fold changes in caspase between different samples. We measured activated caspase 3/7
levels in vehicle- and Staurosporine- (1uM; Sigma Aldrich cat no S6942) treated 2D
cultures with cell counts of 103, 5x103, and 104 cells per well to verify that assay was
linearly dependent in this region (Figure 3.3 panel C). This experiment confirmed that we
can measure caspase levels using as few as 6 microtissues per experimental sample
(roughly 1000 cell per well for 3 technical replicates). We also confirmed that that total
protein content was did not significantly vary between experimental samples due to
factors such as differences in tissue size (CV=0.084; n=4 independent experiments). Only
morphologically intact CMTs were used for this and other assays, and this required
manual selection of CMTs.

3.5.1.1.1 Final Protocol for Caspase 3/7 Measurements
Tissues were treated for 4-12hr with either DMSO or sunitinib to induce
apoptosis. Arrays were washed with DPBS (w/o Ca++, Mg++) to remove residual media. At
least 6 tissues (preferably 12 tissues) were collected per experimental sample and placed
into a 1.5 mL Eppendorf tub containing ~20µl DPBS. Tissues were then re-suspended in
366µl DPBS per tube. An equal volume (366µl) of Caspase-Glo® reagent was added per
tube and samples were pipetted and vortexed to completely lyse tissues. 200ul of sample
was added to a single well of a white-walled 96-well plate (Greiner bio-one, cat no.
655083. Plates were incubated 1hr at room temperature in the dark and then analyzed on
BioTek Synergy H1 Multi-Mode plate reader equipped with Gen5.0 software (Settings:
quick shake, read luminescence, Gain 135, Integration Time 0.01s).
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3.5.1.2 Trypan Blue Exclusion to Detect Late Apoptotic and Necrotic Cells
Measuring caspase 3/7 activation provides us insight into what is occurring during
the early apoptotic phase. We also wish to determine whether these cells complete
apoptosis and/or enter into a necrotic phase. Trypan Blue exclusion is a quick, costeffective method for identifying such cells as the dye will permeate into cells with
damaged membranes much quicker than for cells with intact membranes, staining them
blue, thus making them easily identified under a microscope. CMTs were treated for
longer durations (~24hr) during this experiment to allow progression into post-apoptotic
phase. Whole arrays or individual tissues were digested in a 1mg/mL collagenase IV
(Gibco, cat no. 17104-019) solution in DPBS (with Ca++, Mg++) with 10% FBS for 15min
to digest collagen I. Tissues were further broken down into single cells by dissociating
with 0.05% Trypsin EDTA at 37⁰C with shaking at 200rpm. Cells were centrifuged at
200xg for 5min and re-suspended in CMT culture medium at a concentration of
approximately 5x106 cells per ml. Trypan blue exclusion was performed by mixing 0.7mL
of media with 0.2mL of 0.4% trypan blue (Sigma Aldrich, cat no T-0776) in DPBS and
5µl of cell suspension. The solution was incubated for 1-2 min at room temperature to
allow for labeling of dead cells. The number of blue and white cells was counted (at least
100 counts in total) and the percentage of dead cells was calculated using the following
equation 1:
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3.5.2 Characterizing Changes in Mitochondria Function and ATP Levels with Sunitinib
Treatment
In light of sunitinib’s effects on cellular energy sensing machinery (e.g. AMPK),
we also desired to characterize any metabolic changes. Based on previous findings
discussed in chapter 2, we chose to focus on changes in mitochondria and ATP levels.
These experiments had to be performed in flat 2D cultures, as the assays we utilized were
not adaptable to microtissue culture (see further discussion below).

3.5.2.1 Measuring Changes in Cardiomyocyte Mitochondrial Membrane Potential
Abnormalities in mitochondrial morphology have been cited in the literature, and
there have been some preliminary experiments conducted suggesting that sunitinib can
diminish mitochondrial membrane potential. We adapted the cardiomyocyte cell sorting
protocol originally published by Hattori and colleagues to purify out cardiomyocytes
based on mitochondria membrane potential via FACS [Hattori et al. 2010]. Because
cardiomyocytes are more metabolically active than non-myocytes they express higher
levels of mitochondria. Hattori and colleagues used a lipophilic cell permeable dye to
selectively label the inner membrane of mitochondria, Tetramethylrhodamine, Methyl
Ester Perchlorate (TMRM; Life Technologies, cat no T668). Because this dye labels in
the inner mitochondria, it is also a good marker for mitochondria membrane potential, as
it cannot enter the inner membrane without an intact membrane potential (Figure 3.4
panel A).
We discovered that Hattori’s protocol suffered from limitations such as poor cell
viability during and after cell sorting, which could confound results when a cardiotoxic
agent such as sunitinib was being analyzed (Figure 3.4 panel C). We found that culturing
NRCMs for 24-48hr before FACS and performing FACS in serum-free media, as TMRM
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labeling is not compatible with lipophilic molecules such as serum, significantly
improved viability with negligible effects on CM purity as measured by cardiac troponin I
(cTn-I) staining (Figure 3.4 panels B-C). These improvements helped to ensure that we
would not observe any unwanted decreases in mitochondrial membrane potential during
analysis.
To demonstrate that our protocol could be used to specifically analyze
mitochondrial membrane potential, we conducted experiments with cells treated with a
known disruptor of mitochondria membrane potential, Carbonyl cyanide m-chlorophenyl
hydrazone (CCCP; Sigma-Aldrich, cat no C2759). Of the three TMRM populations we
observe on our histogram plot, we see that CCCP affects primarily the TMRM high
population, cardiomyocytes with high levels of mitochondrial activity. We chose to
analyze changes in this population to characterize changes in mitochondrial membrane
potential for our studies with sunitinib.
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Figure 3.4: Measuring Changes in Mitochondria Membrane Potential via FACS.
A) Density dot plot of neonatal rat heart cells labeled with TMRM (580nm/30) plotted
against autofluoresence (513nm/17). Population P3 represents TMRM high population
consisting of CMs with abundant mitochondrial activity. B) Post-FACS immunolabeling
of cTnI positive cells (red) and nuclear staining (green) to identify all cells to validate
FACS protocol. C) Culturing neonatal rat heart cells post-isolation is critical for
maintaining viability (red bar) post sorting and does not diminish CM purity (blue bar).
D) Left: Characterizing changes in mitochondrial membrane potential using TMRM
labeled cells treated with CCCP, a known disruptor of mitochondrial membrane potential.
Right: This method can be used to identify changes in mitochondria membrane potential
in cells treated with sunitinib.
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3.5.2.1.1 Final Protocol Analyzing Mitochondrial Membrane Potential
NRCMs were cultured in 24-well plates for 24-48hr post isolation before any drug
treatments Cells were treated with 1µM sunitinib for 30min-24hr. We found that using
concentrations in excess of 1µM lead to background interference due to sunitinib autofluorescence. Cells were washed thoroughly with DPBS (no Ca++, Mg++), and labeled with
10nM TMRM in serum free media (3:1 DMEM: M199 (1x), 10mM HEPES, 2mM
Glutamax, 1% Insulin-Transferrin-Selenium Supplement (Gibco, cat no. 51500-056),
100U/mL P/S) at 37⁰C and 5% CO2 for 30min. After the incubation period, cells were
washed again with DPBS (no Ca++, Mg++) and incubated with 0.05% Trypsin EDTA for 3
min at 37⁰C and 5% CO2. We found it critical to only treat with trypsin for <3min as any
membrane damage will cause the TMRM to leak out. Microtissues require too much
enzymatic digestion to obtain single cells; hence they were not used in these experiments.
The trypsin solution was inactivated with a defined trypsin inhibitor solution (Gibco, cat
no R007-100). Cells were collected in serum free media supplemented with 0.1% BSA
(Sigma-Aldrich, cat no. A1470) at concentration of 2.5x106 cells/mL and filtered through
a 70µM mesh filter. Samples were analyzed on a Beckman Dickinson LSRII Flow
Cytometer equipped with a 488nm (blue laser for excitation and 575/26 emission filter to
measure TMRM.

Post-experimental analysis of data was performed using Flow Jo V10 software
(FlowJo LLC). Cellular debris was filtered out using side scatter (SSC) and forward
scatter (FSC) plots (SSC-A vs. FSC-A, Figure 3.5 panel A). Cell doublets were filtered
out using SSC-H vs. SSC-A or SSC-A vs. SSC-W plots (Figure 3.5 panel B). The TMRM
positive population was identified using a 575/26 histogram plot (Figure 3.5 panel C).
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Finally, within the TMRM positive plot, the TMRM high and TMRM low populations
were identified (Figure 3.5 panel D).

Figure 3.5: Determining Changes in TMRM High Population. A) Density dot plot of
neonatal rat heart cells SSC-A vs. FSC-A to remove cell debris from analysis. Numbers
displayed on plot represent % cells falling within gate B) Using SSC-H vs. SSC-A dot
plots to remove doublets from analysis. C) Using TMRM (576/26) histogram to identify
TMRM positive cells. D) Identifying TMRM high population within TMRM positive
parent population.
3.5.2.2 Measuring Changes in Cellular ATP levels
Another method we chose for characterizing the effects of sunitinib on energetics
was to examine changes in cellular ATP levels. This assay is especially important as
sunitinib has been shown to inhibit AMPK activity in vitro, which could lead to depletion
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of ATP levels during times of stress, such as a hypertensive state. Similar to our choice
for a caspase assay, we decided to utilize a luminescence based assay that can be applied
to a few thousand cells. We chose the ATP assay from Calbiochem (EMD Millipore, cat
no 119107) which measures ATP levels from as few as 1000 cells. The assay utilizes
luciferase to catalyze the formation of light from ATP and luciferin, and the light can be
measured using a luminometer (Figure 3.6 panel A).

We first identified the linear working range of the assay using purified ATP
provided by the manufacturer. We found that we can measure as little as 1 picogram of
ATP and stay above background and that the assay performs linearly in the range of 1-104
picograms of ATP (Figure 3.6 panel A). However, we ran into difficulties when trying to
perform this assay with microtissues. Even if we used tissues from the entire 140 well
array, we couldn’t get our luminescence readings (RLU) to fall on the standard curve
(Figure 3.6 panel B). We then switched to performing experiments in 2D, as we wouldn’t
be limited by cell number in such experiments. We assayed ATP levels from vehicle
(DMSO) and treated (1µM sunitinib) cells plated at densities of 105, 3x105, 6x105 cells per
well. We found that 105 cells is sufficient to obtain luminesce readings that fell on the
standard curve. However, with increasing cell densities, the nucleotide releasing buffer
(i.e. lysis buffer) doesn’t seem capable of breaking down this much cellular material, as
our readings didn’t linearly increase as we expected (Figure 3.6 panel C). Hence we
performed all subsequent experiments in 2D at a cell density of 105 cells per well.
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Figure 3.6: Measuring Changes in ATP Levels. A) Standard Curve obtained from using
ATP standards to determine linear region of assay. B) Performing ATP experiments in
CMTs does not yield sufficient signal to fall on standard curve and may not allow us to
distinguish differences between vehicle and sunitinib treated samples. C) Using NRCMs
cultured in 2D flat culture at higher cell densities allow us to see changes in ATP levels
between vehicle (1% DMSO) and treated (1µM sunitinib) cells.
3.5.2.2.1 Final Protocol for Measuring ATP Levels
Based on the considerations above, our final protocol for assaying ATP levels in
2D NRCM cultures is as follows: NRCMs were cultured in 24-well plates and treated
with sunitinib for 24hr. Cells were detached with 0.05% Trypsin-EDTA for 4min at 37⁰C,
5% CO2. Cells were collected and counted and 3x105 cells per experimental sample (3
technical replicates) were aliquoted into 1.5 mL Eppendorf tubes. Cells were centrifuged
at 200xg for 4min to pellet cells and were re-suspended into 30µl DPBS (No Ca++/Mg++).
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Nucleotide releasing buffer (300µl) was added to each tube to lyse cells. Samples were
vortexed or sonicated (Bioruptor® Plus, Diagenode, Inc.) to ensure complete breakdown
of cellular products. ATP monitoring enzyme (3µl) was added to each tube to induce
luciferase reaction. Samples were aliquoted into a white-walled 96-well plate, taking care
to leave at least 1 column and 1 row in between samples. ATP standards in nucleotide
releasing buffer (1-104 picograms) were also aliquoted onto 96-well plates, and ATP
monitoring enzyme was added to these samples as well. Plates were shaken gently for 5
min to ensure mixing and analyzed on a BioTek Synergy H1 Multi-Mode plate reader
equipped with Gen5.0 software (Settings: 10s shake, read luminescence, Gain 100,
Integration Time 0.01s) (BioTek Instruments Inc.).

3.5.3 Characterizing Changes in Microtissue Function following Sunitinib Treatment
3.5.3.1 Measuring Changes in Microtissue Electrophysiology
Our final metric for characterizing microtissue responses to sunitinib was how
tissue functionality is affected. One critical aspect of cardiac biology is the generation of
action potentials, which are required for systolic force generation. Cardiac microtissues
should be able to “capture” an electrical potential and beat synchronously with the signal
provided its frequency is within physiological range (neonatal rat 4-6Hz). Microtissue
arrays were field stimulated by placing 2 carbon electrodes into either side of the array via
drilling holes into the lid of a 35mm dish. Platinum wire attached to the electrodes
connected to anode and cathode leads of stimulator (Muscle Research System, World
Precision Instruments). Electrical stimulation parameters were: biphasic, rectangular
pulse, 15V/cm, 1ms duration, 1ms delay, and 1Hz frequency. Microtissues were analyzed
with respect to spontaneous beating rate (number of contractions counted within 60 sec
interval), excitation threshold (ET, minimum stimulation voltage required for
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synchronous contractions), and maximum capture rate (MCR, maximum beating
frequency). These parameters were assessed starting on microtissue day 2, before and
after treatment with sunitinib using a Nikon TE2000U inverted microscope (Nikon
Corporation) equipped with temperature and CO2 control (37⁰C, 5% CO2).

3.5.3.2 Measuring Changes in Microtissue Force Generation
We also examined changes in force generation due to sunitinib treatment.
Microtissues exert two types of forces: static (diastolic) and active (systolic). Static
tension refers to forces generated in the absence of beating, and is the result of actinmyosin cytoskeletal forces that are generated by all cells, mainly fibroblasts. These forces
control tissue compaction and are thought to be a major contributor to overall tissue
integrity. Static tension was inferred by measuring the displacement of the pillars. Images
were acquired using a 10x Plan Fluor objective on a Nikon TE2000U inverted microscope
equipped with QImaging Exi Blue camera (QImaging) and NIS BR Elements software
(Nikon Corporation). Images were taken from the bottom, middle, and top of the microwells (Figure). The width of a single cap (φ), as well as the separation between caps (S)
and bases of pillars (B) was measured in ImageJ (NIH, imagej.net) in units of pixels
(Figure 3.7 panel A). We derived the displacement (µm) of the pillar using the formula
provided in equation 2, where 0.1706 is the conversion factor between pixels and microns
for the objective used in these experiments.

We then calculated the force using Hooke’s law F=kδ, where δ is the displacement
we calculated in equation 2 and k is the spring constant of the pillar (Figure 3.7 panel B).
The spring constant is a function of the material properties of the pillar and its geometry.
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We directly measured the spring constants of pillars using a Hysitron TI 950
TriboIndenter nanoindenter equipped with a Berkovich tip attached to a force transducer
(Hysitron Inc.). The probe tip is calibrated against a hard surface to determine its elastic
properties. The sample of interest is then loaded (PDMS array) and the probe performs a
“scratch test” where it displaces a single cantilever on the array 14 microns in a horizontal
direction (x-direction). The pillar is displaced four times in both the +x and –x directions.
Based on measured forces exerted on probe from these displacements, as well as knowing
the mechanical properties of the probe, we can directly calculate the spring constant of the
pillar using Hooke’s law.

Figure 3.7: Measuring Forces Generated by CMTs. A) Top: Image of the top of a
microwell allows us to measure cap width (φ) and distance between caps (S). Bottom:
Image of bottom well permits measurement of distance between pillar bases (B). Scale
bar represents 100 microns in both photos. B) Calculating generated forces using
displacement (δ) and pillar spring constants derived from material properties and pillar
geometry.
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For active force measurements, microtissues were electrically paced at 1Hz and
fluorescence (435nm/20 excitation, 480nm/30 emission) video was captured (3 sec, 13
frames per sec, gain 4, exposure time 50ms) using an Exi Blue camera and NIS Elements
BR software to visualize active displacement of beads embedded in pillars. Displacement
of individual beads (in pixels) was calculated using ImageJ software. At least two beads,
on opposite pillars, were analyzed per microtissue and averaged.

3.5.4 Other Analytical Methods
3.5.4.1 Immunocytochemistry
To check the purity of CMs obtained post FACS, cells were labeled with the
cardiac marker cardiac troponin-I (cTn-I, rabbit polyclonal H-170; Santa Cruz
Biotechnology, cat no sc-15368). Briefly, cells obtained from sorting were re-suspended
in CMT media and plated into fibronectin-coated LabTek ™8-well chamber slides
(Thermo Fisher, cat no 154534) at a density of 0.3x106 cells per well and allowed to
attach overnight. The next day, cells were fixed with 2% formaldehyde (Thermo Fisher,
cat no\ 28906) for 15min at room temperature, followed by 3 washes with DPBS (no
Ca++, Mg++). Samples were permeabilized with 0.01% Triton X-100 (Sigma Aldrich, cat
no T9284) in DPBS (no Ca++, Mg++) for 10min at room temperature. To prevent nonspecific binding of secondary antibodies, samples were blocked with 5% normal goat
serum (Cell Signaling Technology, cat no. 5425) in DPBS (no Ca++, Mg++) for 2hr at
room temperature. A polyclonal rabbit cardiac troponin-I antibody (H-170, sc-15368;
Santa Cruz Biotechnology) was used at 1:2000 ratio in Dako Antibody Dilutent (Agilent
Technologies, cat no S0890) and incubated with samples overnight at 4⁰C with gentle
shaking. Samples were then stained with goat anti-rabbit IgG (H+L) rhodamine (TRITC)
conjugate (1:1000 in blocking solution; Jackson Immunoresearch Laboratories, cat no
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111-025-144) for 2hr at room temperature, in the dark. To identify all cells, CMs+ nonmyocytes, samples were counterstained with 1µg/mL 4', 6-diamidino-2-phenylindole
(DAPI; Life Technologies, cat no D21490) for 10min in the dark at room temperature to
label nuclei. Samples were imaged using Leica TCS SP8 laser-scanning confocal
microscope under 20X magnification. An entire well was scanned and individual images
were stitched together. The percentage of cTnI+ cells was determined by manually
counting the number of double stained (TRITC and DAPI positive) and single stained
(DAPI positive only) cells. At least 500 cells were assayed from each well on chamber
slide. At least 2 biological replicates (2 chamber slide wells) were assayed per
experiment.

3.5.4.2 Protein Quantification
While optimizing Caspase-Glo® assay, we had to confirm that that total protein
content was did not significantly vary between experimental samples. We performed
BCA protein assays (Pierce, Thermo Fisher Scientific, cat no 23227) according to
manufacturer’s instructions. Absorbance was measured using a SpectraMax M5
spectrophotometer (Molecular Devices) equipped with Softmax Pro 4.8 software.
Absorbance readings were normalized to the experimental sample with the lowest reading
to create a linear correction factor. We found the correction factor to be unnecessary as
CV of all protein readings across experiments was <0.0833. For ATP assay, protein
readings were performed using Qubit® system (Thermo Fisher Scientific cat no Q33211)
according to manufacturer’s instructions. We generated standard linear correction factors
in the same manner as stated above and used them to normalize calculations for ATP
(pg).
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3.6 Statistical Analysis
All graphs were plotted as mean ± standard deviation (SD); except for box-andwhisker plots where error bars extend from median to min/max value. Individual
experiments measuring caspase 3/7 and ATP levels were conducted on 96-well plates
with 3 technical replicates per experimental sample. In necrosis experiments utilizing
trypan blue exclusion, at least 70 cells were counted per measurement and both chambers
of hemocytometer were assayed to give 2 technical replicates per experimental group. At
least 2 experiments, utilizing different batches of NRCMs, were performed.
Measurements of microtissue function, such as electrical and force generation,
were assayed on individual tissues, which were treated as biological replicates rather than
technical replicates because we found that the variability between tissues within a single
array was far greater than the variability between different arrays. Table 3-1 compares
coefficients of variation (CV) of individual tissues from a single array versus CV between
at least 2 separate arrays for several functional readouts. At least 10-15 tissues were
assayed per array for functional measurements. Additionally, due to inter-tissue
variability, we chose to track the functional changes in individual tissues instead of doing
a bulk average before and after treatment. Accordingly, these data are presented as
percent (%) change from baseline measurements conducted before treatment.
For experiments utilizing flow cytometry, at least 20,000 cells were analyzed per
experimental sample, and the percentage of TMRM high cells was calculated from this
population as described in section 3.4.2.1.1. Statistics were performed from n=3
experimental replicates.
Unpaired two-tail t-tests were performed when appropriate (GraphPad
QuickCalcs, GraphPad Software Inc.). Significance levels were determined between
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sunitinib and vehicle treated samples and were set at *p <0.05, **p < 0.01, ***p <0.001,
and ****p<0.0001 or as otherwise indicated.

Table 3-1 Sources of variability in measurements of microtissue function
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Chapter 4: Creating an In Vitro Model of Human Sunitinib
Cardiotoxicity Using the Rat Cardiac Microtissue Platform
4.1 Rationale
The high prevalence of chemotherapy induced cardiotoxicity observed in patients
can be partly attributed to a lack of preclinical models that can 1) detect early signs of
cardiotoxicity, such as cardiomyocyte apoptosis and decreases in force generation and 2)
identify pivotal mechanisms of sunitinib cardiotoxicity. Identifying pivotal mechanisms
of sunitinib cardiotoxicity using in vivo human clinical trials would not be cost effective
and may raise ethical concerns depending on the hypothesis being tested. Current in vitro
cell culture and animal models suffer from limitations that minimize their usefulness for
modeling human sunitinib cardiotoxicity, such as the ability to incorporate or adequately
control biomechanical loading conditions [Astashkina et al. 2012; Ma et al. 2016; Ogle et
al. 2016; Zhao et al. 2016], an essential facet of cardiac biology. As such, there is a
critical need to develop robust preclinical models that can accurately detect cardiotoxicity
and serve as tools for enhancing our understanding of the mechanisms behind sunitinib
cardiotoxicity.
Therefore, in this chapter we describe the development of an in vitro preclinical
model of human sunitinib cardiotoxicity using a previously established cardiac
microtissue platform. We created 3D cardiac microtissues (CMT) from neonatal rat
cardiomyocytes that self-assemble on silicone (PDMS) cantilevers [Boudou et al. 2012].
We used this system to characterize sunitinib cardiotoxicity using metrics for cell
viability (apoptosis and necrosis) and cardiac function (force generation and
electrophysiology), and examined how these characteristics are impacted by sunitinib
dose and treatment duration.
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4.2 Experimental Procedures
4.2.1 Creating rat cardiac microtissues
Neonatal rat cardiac myocytes were isolated as described in section 3.1.1. Cells
were pre-plated for 1hr at 37⁰C to enrich for cardiomyocytes, and cultured overnight on
fibronectin coated dishes. The next day, cells were washed with PBS (no Ca++ or Mg++)
and media was exchanged to get rid of dead cells leftover from the isolation. Microtissues
were seeded 3hr later according to methods described in section 3.3.1.
4.2.2 Assessment of cell viability in microtissues treated with sunitinib
Microtissues were treated with sunitinib (or DMSO vehicle) 48hr post seeding to
allow for complete tissue compaction and induction of synchronous beating. Activated
caspase 3/7 levels were used as a metric for apoptosis, and were measured using CaspaseGlo® 3/7 assay described in section 3.5.1.1. Tissues were treated with drugs 4-12hr
before assaying for apoptosis. To assess necrosis, tissues were enzymatically dissociated
and stained with trypan blue to determine the percentage of dead cells in microtissues,
according to methods described in section 3.5.1.2. Microtissues treated with 1µM
staurosporine served as positive controls for apoptosis (6hr) and necrosis (24hr).
4.2.3 Assessment of cardiac function in microtissues treated with sunitinib
Baseline measurements of passive and active forces were conducted prior to
treating with sunitinib, 48hr following microtissue seeding, according to methods in
section 3.5.3.2. Post-treatment measurements were taken after 24hr of sunitinib treatment.
Similarly, baseline measurements of electrophysiology (spontaneous beating rate,
excitation threshold, and maximum capture rate) were taken prior to drug treatment, 24
and 48hr post microtissue seeding, according to methods described in 3.5.3.1.
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Figure 4.1 Timeline for rat CMT experiments.

4.3 Results
4.3.1 Rat CMTs recapitulate decreases in cell viability following sunitinib treatment
In cardiac microtissues derived from neonatal rat ventricular myocytes, we first
examined time- and dose-dependent effects of in vitro sunitinib exposure on apoptosis as
indicated by caspase 3/7 activation. We employed staurosporine, a potent apoptosis
inducer, as a positive control. We found that a clinically relevant concentration of
sunitinib (1µM) induced significant activation of caspases 3, 7 though to a lesser degree
than staurosporine (Fig 4.2 panel A). Next, we evaluated how caspase activation is
influenced by sunitinib dose and treatment duration. We found that caspase activation
reaches a maximum level at 8 hours in CMTs treated with 1µM and 10µM sunitinib (Fig
4.2 panel B), so all future experiments examined caspase 3/7 activation at 8 hours
regardless of dose.
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Figure 4.2: Detecting apoptosis in cell viability with sunitinib treatment using a rat
cardiac microtissue model- A) Activated caspase 3/7 levels in response to treatment
with 0.1% DMSO (Vehicle), 1µM sunitinib, or 1µM staurosporine for 8hr (DMSO and
sunitinib) or 6hr (staurosporine); (****p<0.0001 relative to vehicle n=3 experiments;
(*** p<0.001 1µM sunitinib vs. staurosporine n=3 experiments). B) Time dependent
changes in caspase 3/7 activation. Fold changes (relative to vehicle) in caspase levels
were determined for CMTs treated with 1µM or 10µM sunitinib for 4hr, 8hr, or 12hr
[**p<0.01 1µM sunitinib 4hr vs 8hr; *p<0.05 1µM sunitinib 4hr, 8hr vs. 12hr time point;
n=2 experiments (8hr) n=2 experiments (4hr, 12hr); ‡‡p<0.01 10µM sunitinib 4hr vs. 8hr;
‡ p<0.05 10µM sunitinib 4hr, 8hr vs 12hr; n=2 experiments for all time points]. C) Dose
dependent changes in caspase activation in CMTs treated with 50nM, 200nM, 1µM,
10µM sunitinib for 8hr [*p<0.05 50nM vs. 200nM sunitinib n=2 experiments; *p<0.05
200nM vs. 1µM sunitinib n=2 experiments (200nM) n=4 experiments (1uM); **p<0.01
1µM, vs.10µM sunitinib n=4 experiments (1uM), n=2 (10uM) experiments]. D) Nonlinear curve fitting of panel C results yielded a log2 function (gray line), R2=0.993.
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When examining how caspase activation is influenced by sunitinib dose, we
determined that 50nM is the threshold concentration for caspase activation for our model;
and observed dose dependent increases in caspase 3/7 activation in the range 50nM to
10µM sunitinib (Fig 4.2 panel C). Doses greater than 10µM were not deemed
physiologically relevant to humans given observed concentrations of sunitinib in human
blood are typically 0.1-1.89µM. Interestingly, we found that the degree of caspase
activation correlated strongly with sunitinib dose. Using non-linear curve fitting methods,
we discovered that our results fit strongly with a logarithmic (log2) function that produces
an R2 value >0.99 (Fig 4.2 panel D). Finally, we found increased numbers of late
apoptotic/necrotic cells in CMTs treated with 10µM sunitinib as compared to vehicle
(DMSO) treated cells after dissociating CMTs and staining with trypan blue (Fig 4.3).
Collectively, these results demonstrate the ability of the rat microtissue model to detect
decreases in viability due to sunitinib treatment that is dependent on sunitinib dose and
treatment duration, and established dose and treatment duration for subsequent
experiments.
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Figure 4.3: Late apoptosis and necrosis in rat cardiac microtissues treated with
sunitinib. Detecting necrotic/late apoptotic cells. CMTs were dissociated following 24hr
treatment with 10µM sunitinib or 1µM staurosporine and the percentage of cells stained
with trypan blue was manually measured and normalized to vehicle levels to express as a
fold change [**p<0.01 10µM sunitinib vs. 1µM staurosporine (n=2 experiments);
***p<0.001 vehicle vs. 10µM sunitinib n=2 experiments (sunitinib) n=3 experiments
(vehicle)].

4.3.2 CMTs reveal changes in cardiac function following sunitinib treatment
LV dysfunction remains an important toxicity of sunitinib treatment; however
there are a limited number of studies characterizing changes in myocyte force generation.
Accordingly, in this part of our study, we modeled changes in microtissue force
generation and electrophysiology using the microtissue model. We found that 1µM
sunitinib was sufficient to decrease the spontaneous beating rates of microtissues, and
beating rates continued to decline in a dose dependent manner (Fig 4.4 panel A), with
complete arrest at 10µM sunitinib. Static (diastolic) forces generated by microtissues also
decreased in a dose dependent manner (Fig 4.4 panel B). We found that active (systolic)
force generation increased during the 24hr treatment period, which we attribute to tissues
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maturing over time. Microtissues treated with 10µM sunitinib showed significantly
smaller increases in force generation (Fig 4.4 panel B). When microtissues were subjected
to field stimulation we found no significant differences in excitation threshold nor
maximum capture rate between vehicle and sunitinib treated tissues (Fig 4.4 panel c-d).
Results from figures 4.2-4.4 suggest that the rat cardiac microtissue model may serve as a
robust tool for early detection of drug induced cardiotoxicity, as it can detect changes in
cell viability and cardiac function.
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Figure 4.4: Modeling variations in cardiac function following administration of
sunitinib in rat CMTs- A) Dose dependent decreases in spontaneous beating rates
following 24hr of treatment with 0.1% DMSO (vehicle n=10 tissues), 1µM sunitinib
(n=11 tissues), or 10µM sunitinib (n=11 tissues) (**** p<0.0001 vs. vehicle; *p<0.05
1µM sunitinib vs 10µM sunitinib). B) Dose dependent decreases in static (diastolic)
tension generated by CMTs treated for 24hr with 0.1% DMSO (n=12 tissues), 1µM
sunitinib (n=20 tissues), or 10µM (n=10 tissues) sunitinib (**p<0.01 vehicle vs 1µM
sunitinib, 1µM sunitinib vs. 10µM sunitinib; ****p<0.0001 vehicle vs 10µM sunitinib).
Decrease in active (systolic) tension with 10µM sunitinib treatment [****p<0.0001
vehicle (n=4 tissues) or 1µM sunitinib (n=5 tissues) vs. 10µM sunitinib (n=9 tissues)]. We
did not observe any changes in C) Excitation Threshold or D) Maximum Capture Rate
following 24hr treatment with 0.1% DMSO or 10µM sunitinib. Data in panels A and C
are plotted as box-and-whisker plots; Median-1st Quartile are plotted in red, 3rd QuartileMedian are plotted in green, error bars extent from median to min/max.
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4.4 Discussion
Currently, more than 100,000 people have been treated with sunitinib, and there
are over 100 open clinical trials with this drug (clinicaltrials.org); a fact that stresses the
notion that we need to improve our understanding of sunitinib cardiotoxicity. Many basic
and translational studies in cardio-oncology are constrained by inadequate preclinical
models. Animal models do not allow for precise control over biomechanical and
biochemical factors [Houser et al. 2012]. Likewise, the use of 2-dimensional (2D) cell
cultures for the study of sunitinib cardiotoxicity also suffers from serious shortcomings.
Most important is the inability to incorporate essential features of cardiac physiology such
as the application of mechanical preload and afterload [Ma et al 2016]. Taking advantage
of recent advances in tissue engineering, we created in 3-dimensional (3D) CMTs that
better mimic in vivo conditions without sacrificing control over cellular, biochemical, and
mechanical inputs [Legant et al. 2008; Boudou et al. 2012]. Using the CMT platform, we
successfully created a preclinical model for characterizing sunitinib toxicity. In the next
chapter we will be using this model to gain insights into the mechanisms of sunitinib
cardiotoxicity while establishing a template for broader preclinical analysis of
cardiotoxicity for the thousands of tyrosine kinase inhibitors currently in development.

We first confirmed that our microtissue model could recapitulate previously
observed increases in cell death with sunitinib treatment. Our model was able to detect
significant increases in caspase 3/7 activation following treatment of physiological doses
of sunitinib, which is consistent with reports by Hassinoff et al. and Dohertry et al.
[Hassinoff et al. 2008; Doherty et al. 2013]. We are the first to report that the degree of
caspase 3/7 activation correlates logarithmically (log2) with sunitinib dose. Additionally
we found that caspase activation was time dependent, a finding that also observed by
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Hassinoff and colleagues [Hassinoff et al. 2008]. Our results also demonstrated that many
of these early apoptotic cells go on to become non-viable, leading to cardiomyocyte loss,
which is consistent with studies reporting elevated troponin levels in patients [Chu et al.
2007], CK-MB elevations in rodent studies [Maayah et al. 2014], and increases in
TUNEL positive cells in in vitro NVRM studies [Chu et al. 2007]. In summary, our
microtissue model detects activation of apoptosis pathways and cell death with sunitinib
treatment and our results are in-line with existing studies in the literature, while still
providing some novel findings regarding the relationship between sunitinib dose and
activation of apoptosis.
Our microtissue model detected dose dependent decreases in spontaneous beating
rate and full cardiac arrest at 10µM sunitinib, which is consistent with findings by
Doherty and colleagues [Doherty et al. 2013]. These dose-dependent decreases in beating
may have been connected to findings that sunitinib blocks hERG channels at
physiological doses (see section 2.1.2.1 for more details). Neonatal rodent cells do
possess a small hERG current and blocking it has been shown to lead to arrhythmias [Lin
et al. 2010; Gilchrist et al. 2015]. Because we did not measure action potential waveforms
in this experiment, we cannot be certain that our findings are due to hERG channel
blockage. Interestingly, we found no difference in electrophysiology parameters such as
excitation threshold and maximum capture rate, both of which are measured under field
stimulation. These results suggest that in the presence of an outside current, sunitinib’s
effects on electrophysiology are limited. Furthermore, sunitinib has been primarily
shown to induce atrial fibrillation, and CMTs we created are primarily of ventricular
phenotype [Tamargo et al. 2015], so that may explain why we didn’t observe more
dramatic effects on some electrophysiology parameters.
In addition to changes in electrophysiology, we also observed dose dependent
decreases in static (diastolic) tension generated by microtissues. Static tension is a
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measure of forces exerted by tissue at rest and would be influenced by cardiomyocyte
loss. We cannot ascertain whether myocyte loss is solely responsible for observed
decreases or if other mechanisms contribute to reduced force generation. Our findings for
tension partially differ from those of Rainer and colleagues who reported decreases in
systolic but not diastolic stresses in short term (30min) sunitinib experiments (doses
≥1.87µM) performed on human atrial muscle strips, but many differences in experimental
preparation may have contributed to the differences observed [Rainer et al. 2012].

4.5 Limitations and Conclusions
4.5.1 Study Limitations
One limitation in this study is the use of neonatal rat cells to model adult human
cardiotoxicity. In the absence of an adult human cardiomyocyte cell line, NRCMs have
been utilized for years and are able to recapitulate many aspects of human cardiac biology
Nevertheless, there are valid concerns about potential inter-species differences. Though
cardiac myocytes derived from human pluripotent derived cardiac stem cells mitigate the
species difference, these cells are functionally immature. Another limitation in our work
is the inability to distinguish between dead cells and “sick” cells in our functional data.
We cannot discern whether cells are becoming “sick” due to sunitinib and can’t generate
as much force per cell, or whether there are fewer live cells contributing to force
generation. However, our results demonstrating that sunitinib decreases spontaneous
beating rate may give us some insight into this issue. In the case of spontaneous beating
rate, we are only looking at the function of live cells, as the dead cells cannot beat. Our
results clearly demonstrate a decrease in the beating rates of live cells in CMTs treated
with sunitinib. This result suggests that sunitinib is making cells “sick” and less
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functional. Hence it may be possible that sunitinib is impacting myocyte force generation
independent of myocyte attrition due to apoptosis. Another limitation with the microtissue
model is the inability measure systolic tension at a fixed tissue length. Because of the
decrease in diastolic tension we were concerned that sarcomere lengths were also
changed, which in itself would affect systolic tension due to the Frank-Starling
relationship [Brady et al. 1991]. Therefore, the effects of sunitinib on active force
generation can be confounded by any changes in static tension. For example, if sunitinib
causes decreases in static tension that lead to increases in sarcomere length, that
sarcomere change alone will tend to increase active force generation. If sunitinib is
actually directly decreasing active force generation, we may not be able to observe this
decrease because of the increase in sarcomere length favoring increased active force
generation. Ideally, to separate out length-dependent changes of active tension, these
measurements must be performed on tissues of a fixed length. We currently do not have
to capability to manipulate microtissues in this manner.

4.5.2 Conclusions
As tyrosine kinase inhibitors such as sunitinib continue to be widely used in the
treatment of cancer, better preclinical models for identifying the risks and mechanisms of
cardiotoxicity will be very important. We have created an in vitro model of sunitinib
cardiotoxicity that allows us to identify effects on cell viability and cardiac function. We
were able to recapitulate decreases in myocyte viability and function that were described
in previous studies and we were the first group to fully characterize the effects of
sunitinib dose and duration on cardiomyocyte loss and function. The model described in
this study may also serve as robust tools for disease modeling.

80

Chapter 5: Identifying Pivotal Mechanisms of Sunitinib
Cardiotoxicity: Contributions of Afterload and Mitochondria
Dysfunction

5.1 Rationale
In humans, sunitinib causes increases in blood pressure, and induces hypertension
in up to 47% of treated individuals [Bono et al. 2011; Demetri et al. 2006; Di Lorenzo et
al. 2011]. A small cohort of these patients goes on to develop LV dysfunction (<10%)
[Shah RR et al 2015; Telli et al. 2008; Hall et al. 2013]. However, the direct interaction
between load and cardiac dysfunction in the setting of sunitinib remains completely
unknown. Hypertension induces the heart to generate greater forces, and it is well
documented that increased afterload is risk factor for eventual LV dysfunction [Ozkan et
al. 2011; Fernandes-Silva et al. 2016]. The question of whether the development of
hypertension merely coincides with sunitinib toxicity or if increased afterload directly
potentiates the risk of cardiac toxicity for any specific dose/duration has important
clinical relevance. We hypothesized that increased afterload will augment the cardiotoxic
effects of sunitinib.
In addition to afterload, mitochondrial dysfunction is thought to be another
mechanism for sunitinib cardiotoxicity. Endomyocardial biopsies from patients being
treated with sunitinib have revealed swollen mitochondria, and in vitro studies with
sunitinib have revealed qualitative changes in mitochondrial membrane potential [Chu et
al. 2007; Kerkela et al. 2009]. However, mitochondria dysfunction as it relates to
sunitinib has not been fully characterized.
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Therefore, in this chapter we assessed the contributions of afterload and
mitochondria dysfunction in the context of sunitinib cardiotoxicity. We were able to
create cantilevers with different stiffnesses to vary the amount of afterload experienced by
microtissues. We used apoptosis, via caspase 3/7 activation, as a metric for characterizing
the cardiotoxic effects of afterload. In the second part of this chapter, we quantitatively
characterized mitochondria dysfunction with sunitinib treatment using our own advances
in mitochondria labeling and flow cytometry. We evaluated mitochondrial function
changes with sunitinib treatment duration. We then looked at the impact of mitochondrial
dysfunction on cell energetics by measuring cellular ATP levels. Finally, we evaluated
whether upstream activation of AMPK, using molecule AICAR, could rescue sunitinib
induced caspase 3/7 activation.

5.2 Experimental Methods
5.2.1 Characterizing mitochondrial dysfunction
In these experiments, NRCMs were cultured in flat culture in 24-well plates for
48hr post isolation. Cells were treated with 1µM sunitinib for 30min-24hr and
subsequently labeled with TMRM to identify quantitative changes in mitochondria
membrane potential as described in section 3.4.2.1.1. Cells treated with 50µM CCCP
were used as a positive control for membrane potential disruption in these experiments.
ATP levels were measured after 24hr treatment with sunitinib as described in section
3.5.2.2.1. We also explored the ability of the AMPK activator AICAR to reduce sunitinib
induced caspase activity as described in section 4.2.2.
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5.2.2 Creating microtissues under varying degrees of afterload
Devices were fabricated using either a 5:1 or 15:1 base-to-curing ratio to create
arrays with stiff or soft pillars respectively. The resulting spring constants from these
pillar configurations were 1.16157±0.09821 N/m (28 pillars tested) for stiff pillars and
0.55982±0.17612 N/m for soft pillars (20 pillars tested), as measured by nanoindentation
as described in section 3.5.3.2. Rat cardiac microtissues were seeded in the same manner
as described in section 4.2.1.
5.2.3 Assessing the Contribution of Afterload
We chose to characterize the effect of afterload on sunitinib cardiotoxicity in
terms of apoptosis, specifically caspase 3/7 activation. Activated caspase 3/7 was
measured using Caspase-Glo® 3/7 assay as described in sections 3.5.1.1 and 4.2.2.

5.3 Results
5.3.1 Sunitinib induces decreases in mitochondrial membrane potential and cellular ATP
levels
Recognizing that mitochondrial dysfunction is a proposed mechanism of sunitinib
cardiotoxicity, we assayed mitochondrial membrane potential in NVRMs at various time
points following treatment with 1µM sunitinib using TMRM and a flow cytometric
analysis. When mitochondria membrane potential is impaired, TMRM will not be able to
label the inner membrane of mitochondria. We used (CCCP), a known disruptor of
mitochondrial membrane potential, as a positive control for these experiments. Figure 5.1
(panel A) shows a typical histogram of TMRM levels in vehicle, sunitinib (1µM), and
CCCP (50µM) treated NVRMs. The plot demonstrates modest decreases in mitochondrial
membrane potential with 1uM sunitinib treatment; albeit this decrease is not as significant
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as one observed with CCCP treated cells. We hypothesized that like caspase activation,
mitochondrial membrane potential may also exhibit time dependent changes, therefore we
quantified differences in mitochondrial membrane potential between vehicle and sunitinib
treated cells across various time points (Fig 5.1 panel B). We found significant decreases
in mitochondria membrane potential at 4 hour and 8 hour treatment durations, but none
before or after this time interval. Interestingly, these time points also correspond to when
we observed caspase 3/7 activation. We also observed modest decreases in cellular ATP
levels in NVRMs treated with 1uM sunitinib for 24hr (Fig 5.1 panel C).
Previous studies have identified the inhibition of AMPK activity as an off target
effect of sunitinib, which is another possible explanation for decreased ATP levels. We
hypothesized that treating CMTs with an AMPK activator, AICAR, could reverse some
of the observed cardiotoxic effects of sunitinib, specifically caspase 3/7 activation.
However, upstream activation of AMPK with AICAR was not sufficient to attenuate
caspase 3/7 activation in sunitinib treated cells (Fig 5.1 panel D). Our results reveal time
dependent changes in mitochondrial membrane potential with sunitinib treatment, which
may contribute to observed decreases in cellular ATP levels.
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Figure 5.1: Characterizing changes in mitochondrial function and cell energetics
with sunitinib treatment– A) Flow cytometry histogram showing levels of TMRM, a
dye used to measure mitochondrial membrane potential. NVRMs grown in flat culture
were treated with 0.1% DMSO (vehicle), 1µM sunitinib, or 50µM CCCP (known
disruptor of mitochondria membrane potential) for 30min (CCCP) or 4hr (DMSO and
sunitinib) and then were labeled with 10nM TMRM. B) Time dependent decreases in
mitochondria membrane potential following treatment with 1uM sunitinib. NVRMs
grown in flat culture were treated with 0.1% DMSO or 1µM Sunitinib for 30min-24hr and
labeled with TMRM to assess mitochondria membrane potential (*p<0.05 n=3
experiments). C) Decreases in ATP levels in NVRMs following 24hr treatment with 1µM
sunitinib (*p<0.05 n=3 experiments). D) Upstream activation of AMPK with molecule
AICAR did not reverse sunitinib induced caspase activation in rat CMTs (n=2
experiments).
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5.3.2 Cardiotoxic effects of sunitinib are augmented by increased afterload in CMT model
Though hypertension frequently accompanies sunitinib treatment and most
patients with sunitinib-induced cardiotoxicity have hypertension, it remains unclear
whether hypertension is a marker or a mediator of cardiac dysfunction. Recognizing that
the stiffness of the cantilever is the primary load constraining active shortening of the
tissue (i.e. afterload), we cultured CMTs for 48hr on stiff (5:1 base-to-curing ratio) and
soft (15:1 base-to curing-ratio) pillars and treated them with either 0.1% DMSO (vehicle)
or 1µM sunitinib for 8 hours. Figure 5.2 (panel A) shows caspase 3/7 activation for this
experiment. In vehicle treated CMTs, we see greater caspase activation in soft pillars
versus stiff pillars. However, in sunitinib treated tissues, we observed greater caspase
activation in stiff versus soft pillars. When this data is graphed as a fold change (Fig 5.2
panel B), we see that increased afterload augments sunitinib-induced caspase 3/7
activation. These results suggest that increased afterload augments the myocardial toxicity
associated with a given dose and duration of sunitinib.
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Figure 5.2: Using CMTs to assess the contribution of afterload to observed
cardiotoxic effects of sunitinib- A) rat CMTs cultured on stiff (5:1) or soft (15:1) pillars
were treated with 0.1% DMSO (vehicle) or 1µM sunitinib for 8hr. Differences in active
caspase 3/7 levels were observed between soft and stiff vehicle treated CMTs (** p<0.01;
n=3 experiments) and sunitinib treated CMTs (*** p<0.001; n=3 experiments). B)
Results in part A) plotted as fold changes in active caspases 3/7 relative to vehicle treated
CMTs (**p<0.01 n=3 experiments).
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5.4 Discussion
In addition to creating a preclinical model for sunitinib we also wanted to gain
mechanistic insights to sunitinib cardiotoxicity. Our findings of modest, yet significant,
decreases in mitochondrial membrane potential with sunitinib treatment complements
patient biopsies showing swollen mitochondria and in vitro studies showing qualitative
decreases in mitochondrial membrane potential at a single time point [Kerkela et al. 2009;
Chu et al. 2007; French et al. 2010]. To our knowledge, we are the first group to define
the time-dependence of changes in mitochondrial membrane potential following sunitinib.
Interestingly, decreases in mitochondrial membrane potential corresponded to same time
points when we observed caspase activation. It has been previously shown that activated
caspases 3 and 7 are key mediators of mitochondrial apoptosis events, such as decreases
in membrane potential [French et al. 2010; Lakanhi et al. 2006; Safiulina et al. 2006].
Mitochondrial swelling has been shown to accompany loss in membrane potential. Future
work would need to done to separate out the direct effects of sunitinib on mitochondrial
function vs. indirect effects on mitochondria due to sunitinib-induced apoptosis. One
experiment that may be useful to distinguish these two mechanisms would be to treat
NRCMs with a caspase 3/7 inhibitor prior to administration of sunitinib. If mitochondria
function is still impaired in the absence of caspase activation, then sunitinib is more likely
to be directly impacting mitochondrial function, as opposed to indirectly via caspase 3/7
activation.
We further observed modest decreases in ATP levels, similar to those reported by
Kerkela and colleagues [Kerkela et al. 2009], and these may be consequent to the changes
in mitochondrial membrane integrity. Another possible explanation for decreases in ATP
levels is AMPK inhibition by sunitinib (IC50=0.062±0.029µM for rat [Laderoute et al.
2010]). Cohen and colleagues reported that sunitinib cardiotoxicity could be rescued by
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the addition of an upstream AMPK activator, AICAR [Cohen et al. 2011]. In our
experiments with AICAR treatment, we found no significant change in caspase 3/7
activation. Interestingly our results appear to support findings by Kerkela and colleagues
[Kerkela et al. 2009], who report that sunitinib affects intrinsic kinase activity. Perhaps
upstream activation of AMPK by AICAR is not properly targeting the mode of sunitinib’s
inhibition of AMPK, and a different AMPK activator should instead be used. In
summary, our characterization of mitochondrial dysfunction in NRCMs ties together our
caspase results from microtissues as well as previous findings of swollen mitochondria
and decreased ATP levels.
The CMT model is particularly well-suited for examining whether increases in
afterload augment cardiotoxic effects of sunitinib. We varied afterload by altering the
stiffness of the pillars on which CMTs are tethered. We observed an increased magnitude
of sunitinib-associated caspase activation with pillars. When CMTs are cultured on stiff
pillars in the absence of sunitinib, we actually observed somewhat lower caspase
activation, further supporting an interaction between sunitinib and increased afterload.
More specifically, the switch in increased apoptosis from soft to stiff pillars following
sunitinib treatment suggests that sunitinib may be impairing normal adaptive responses to
increased afterload. Increased mechanical forces, such as afterload, have been shown to
promote the formation and maturation of focal adhesions, which are adhesions between
cellular integrins and ECM molecules. Tyrosine kinases, Src and focal adhesion kinases
(FAK) are recruited to these focal adhesions and are activated via phosphorylation.
Activated Src and FAK can inhibit apoptosis via MAPK/ERK pathway [Aikawa et al.
1997]. This could explain why we saw lower caspase activation on stiff pillars: the
increased afterload may have resulted in greater levels of activated Src and FAK
[Franchini et al. 2000]. It appears that sunitinib can inhibit these tyrosine kinases, though
to a lesser degree than its effects on RTKs. For example, in a model of glioblastoma,
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treatment with 10µM sunitinib led to decreased levels of activated FAK and Src [de
Boürd et al. 2007]. Perhaps inhibition of the anti-apoptotic effects of Src and FAK by
sunitinib can explain why we observed greater caspase activation on stiff pillars following
sunitinib treatment even though caspase levels on stiff pillars was in fact lower in vehicle
treated groups.
Our results are in line with previous rodent studies that found that concurrent
administration of a vasopressor (phenylephrine) was required to observe LV dysfunction
with sunitinib [Doherty et al. 2013; Khakoo et al. 2008], which suggest that afterload is a
key mediator of sunitinib’s effects on LV function. It is tempting to speculate that the
energetic stress caused by decreased in ATP generation (due to sunitinib) combined with
an increased bioenergetics demand induced by increased afterload reach the threshold for
inducing caspase activation. Even in the absence of definitive proof for this speculation,
our findings support a more aggressive treatment of hypertension in patients treated with
sunitinib to prevent (or limit) LV dysfunction.

5.5 Limitations and Conclusions
5.5.1 Study Limitations
One major limitation in the study was the inability to conduct experiments relating
to mitochondrial membrane potential and ATP measurements with CMTs. Flow
cytometry required a single cell suspension and digesting microtissues enzymatically
resulted in TMRM dye leaking out. ATP measurements required an abundance of cells
that we could not obtain with CMTs. Additionally, in these experiments, we found that
dosing cells with concentrations >1µM sunitinib resulted in significant background
fluorescence. Hence we only conducted these experiments at the 1µM sunitinib level.
90

Fortunately, this is a clinically relevant concentration of sunitinib. Finally, with regard to
our experiments with afterload, we realize our study would hold more clinical relevance if
we could induce changes in afterload after CMT formation instead of creating CMTs on
different in the presence of different pillar stiffness, because secondary changes in
cantilever stiffness would better mimic the secondary development of hypertension after
sunitinib exposure. The ability to induce secondary changes in afterload is an active area
of investigation in our research group.

5.5.2 Conclusions
Many studies cite an association between developing hypertension and the
eventual development of LV dysfunction during or after sunitinib treatment. The
contribution of increased afterload to sunitinib’s cardiotoxic effects has been
understudied. Though it is possible that higher afterload in vivo simply unmasks LV
dysfunction induced by sunitinib, our findings support the concept that increased
afterload actually augments cardiotoxicity of sunitinib. Our results suggest that
management of hypertension may be important for preventing eventual LV dysfunction in
patients receiving sunitinib. Additionally, we are the first group to fully characterize loss
of mitochondrial membrane potential with sunitinib treatment, and relate the temporal
pattern of these changes to the timing of caspase activation following sunitinib exposure.
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Chapter 6: Analyzing Responses of Human Cardiac
Microtissues to Sunitinib
6.1 Rationale
Although neonatal rat cardiomyocytes do recapitulate most of the essential
features of cardiac physiology, the clinical relevance our rat cardiac microtissue model
may ultimately be limited by inter-species differences between rodents and humans
[Houser et al. 2012]. In the absence of a human cardiomyocyte cell line, researchers have
begun creating sources of human cardiomyocytes by differentiating pluripotent stem cells.
As section 2.3.2 discussed, these pluripotent derived cardiomyocytes are immature (fetallike) and do not recapitulate many features of adult cardiac biology [Yang et al. 2014].
Nevertheless, these cells are currently being utilized to study responses to
pharmacological agents, and their ability to be incorporated into 3-dimensional constructs
tends to help them mature compared with 2-dimensional culture conditions [Burridge et
al. 2016; Broekel et al. 2016; Fong AH et al. 2016]. For this reason, we felt that it was
important to start transitioning our cardiac microtissue model to include studies with
CMTs composed of human cardiac cell sources.
Therefore, in this chapter we examined the responses of human CMTs to sunitinib
using caspase 3/7 activation as our primary metric for cardiotoxicity. We compared
sensitivity of human and neonatal rat CMTs. Finally, we assessed how caspase activation
in response to sunitinib is impacted by afterload in human CMTs.
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6.2 Experimental Methods
6.2.1 Creating human cardiac microtissues
Human cardiomyocytes were derived from pluripotent stem cells according to the
differentiation protocol described in section 3.1.2. These cardiomyocytes were mixed
with human mesenchymal stem cells (MSCs) to create tissues that were 93% CM / 7%
MSCs. Microtissues were seeded according to methods described in section 3.3.2.
Microtissues were treated with sunitinib on day 5 of microtissue culture.
6.2.2 Assessing the Contribution of Afterload
Devices were fabricated using either a 5:1 or 15:1 base-to-curing ratio to create
arrays with stiff or soft pillars respectively, as described in section 5.2.1. We chose to
characterize the effect of afterload on sunitinib cardiotoxicity in terms of apoptosis,
specifically caspase 3/7 activation. Activated caspase 3/7 was measured using CaspaseGlo® 3/7 assay as described in sections 3.5.1.1 and 4.2.2.

6.3 Results
6.3.1 CMTs composed of human pluripotent stem cell derived cardiomyocytes exhibit
afterload dependent capsase 3/7 activation following sunitinib treatment
To extend these observations, we created CMTs composed of human iPS derived
cardiomyocytes mixed with human mesenchymal stem cells (huMSCs) and examined
their responses to sunitinib. Human CMTs treated with 1µM and 10µM sunitinib for 8hr
exhibited significant elevations in caspase 3/7 levels (Fig 6.1 panel A). When we
compared these responses to ones we obtained with rat CMTs treated at same
concentration of sunitinib, we found that human CMTs have nearly 3-fold greater caspase
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activation than rat CMTs at the 10µM dose. When human CMTs are treated with a more
physiologically relevant dose of sunitinib (1µM), we found that caspase activation is very
similar to what we observed in rat CMTs (Fig 6.1 panel A). These results suggest that
human CMTs exhibit robust responses to sunitinib treatment.
Next we sought to address our hypothesis that increased afterload augments
sunitinib cardiotoxicity in human CMTs. Human CMTs were cultured on stiff (5:1
PDMS) or soft pillars (15:1) for 5 days before being treated with 1µM sunitinib for 8
hours. We found that human CMTs cultured on stiff pillars exhibited a nearly 3-fold
increase in caspase 3/7 activation following sunitinib treatment compared to human
CMTs cultured on soft pillars (Fig 6.1 panel B). In fact, caspase 3/7 levels were
minimally increased (1.15±0.078 fold change) following sunitinib treatment in human
CMTs cultured on soft pillars. This finding varies from what we observed in rat CMTs,
where caspase 3/7 levels did increase following sunitinib treatment (1.74±0.064 fold
change). In summary, increase afterload augments sunitinib induced caspase 3/7
activation in human CMTs.
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Figure 6.1: Sunitinib cardiotoxicity in CMTs composed of human pluripotent
derived cardiomyocytes (iPS-CMs) - Differentiation day 20-30 iPS-CMs derived from
SV20 iPS cell line were combined with 7% huMSCs to create human CMTs. A) Fold
changes in activated caspase 3/7 levels of human CMTs on stiff pillars treated 8hr with
0.1% DMSO (vehicle) or 1µM, 10µM sunitinib for 8 hours compared to neonatal rat
CMTs [**p=0.0116 10µM sunitinib human CMTs (n=2 experiments) vs. neonatal rat
CMTs (n=2 experiments)]. B) Human CMTs were cultured on stiff (5:1) or soft pillars
(15:1) and treated with 1µM sunitinib for 8hr. Plotted are fold changes (relative to
vehicle) in caspase 3/7 levels in human and rat CMTs [**p<0.01 human CMTs on stiff vs.
soft pillars (n=2 experiments); **p<0.001 human CMTs (n=2 experiments) vs. neonatal
rat CMTs (n=3 experiments) cultured on soft pillars].
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6.4 Discussion
The final part of our study was aimed at examining responses of human
pluripotent derived cardiomyocytes to sunitinib. We found the human CMTs exhibited
significant activation of caspase 3/7 in response to 10µM sunitinib, more than 3 times
what we observed in rat CMTs (Fig 6.1 panel A). It’s possible that this difference is
species-related or maturation-related. Such differences could impact sensitivity to
cardiotoxic agents like sunitinib. Our results are in stark contrast to other studies utilizing
iPS-CMs that required much higher concentrations of sunitinib to see decreases in cell
viability (caspase activation and/or LDH release) in 2D cultures. For example, Cohen and
colleagues had to dose flat cultures of iPS-CMs with 23µM sunitinib to get a 2 fold
activation of caspase 3/7, which is well outside physiological range of sunitinib
concentrations observed in vivo, making their results less clinically relevant (Cohen et al.
2011). The human CMT model, on the other hand, displayed more than a 2-fold increase
in caspase 3/7 activation with just 1µM sunitinib (on stiff pillars). These differences may
be due to differences in iPS-CM derivation and/or choice of culture platform (2D vs. 3D),
but it is tempting to speculate that the biomechanical loading intrinsic to the CMT model
(and clinical sunitinib use) is an important regulator of sunitinib cardiac toxicity. Such
speculation is further supported by our finding that increased afterload not only augments,
but is required for sunitinib induced caspase 3/7 activation in human CMTs (Fig 6.1 panel
B). The dependence of cardiotoxicity on afterload correlates well to clinical findings that
hypertension is associated with the eventual development of LV dysfunction. Our results
suggest that human CMTs with capacity for adjusting in vitro afterload represent an
important advance for modeling human sunitinib cardiotoxicity.
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6.5 Limitations and Conclusions
One major limitation associated with pluripotent derived cardiomyocytes is that
they are fetal-like in nature and do not exhibit all of the hallmarks of adult cardiomyocyte
physiology. Therefore their responses to pharmacological agents may differ from the
response of an in vivo adult heart. Nevertheless, we believe that iPS-CMs are suitable to
use in experiments primarily focused on examining effects of sunitinib on cell viability.
Additionally, in our experiments examining the contribution of afterload to sunitinib
toxicity, we would preferentially perform these experiments using secondary changes in
afterload, as we discussed earlier in section 5.4. Proposed methods for inducing secondary
afterload changes in CMTs will be discussed in the next chapter. Despite these
limitations, our finding that human CMTs experience afterload dependent caspase
activation in response to sunitinib supports clinical findings that hypertension, in many
cases, is a predictor of future LV dysfunction. The fact that our CMT model recapitulates
this finding makes it a useful tool for studying sunitinib induced cardiotoxicity.
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Chapter 7: Conclusions and Future Work
7.1 Summary of work
Cardiotoxicity remains an important detrimental clinical consequence of
chemotherapy treatment. Sunitinib, a multi-targeted oral tyrosine kinase inhibitor used to
treat renal cell carcinoma and gastrointestinal stromal tumors, is associated with
hypertension in up to 43% of patients and left ventricular dysfunction in up to 9.7% of
patients. Current preclinical models, such as animal models and in vitro cell culture
models are not well-equipped for identifying and characterizing pivotal mechanisms of
sunitinib induced cardiotoxicity. Thus, our current understanding of sunitinib
cardiotoxicity is limited; in particular our understanding of the role of alterations in
mechanical loading and mitochondrial function is very limited. This dissertation centered
on: 1) Creating a preclinical model of human sunitinib cardiotoxicity using engineered
tissues; and 2) Elucidating the roles of mitochondrial dysfunction and increased
mechanical loading in the context of sunitinib cardiotoxicity.
7.1.1 Creating a preclinical model of human sunitinib cardiotoxicity using engineered
tissues
In Chapter 4 we described the development of an in vitro preclinical model of
human sunitinib cardiotoxicity using a previously established cardiac microtissue
platform where 3D cardiac microtissues (CMT) could be formed from neonatal rat
cardiomyocytes. We used this system to characterize sunitinib cardiotoxicity using
metrics for cell viability (apoptosis and necrosis) and cardiac function (force generation
and electrophysiology), and examined how these characteristics are impacted by sunitinib
dose and treatment duration.
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We found that as little as 50nM sunitinib was sufficient to induce caspase 3/7
activation (1.43 ±0.10 fold increase over vehicle), which is well within the range of
sunitinib concentrations found in human blood plasma [Faivre et al. 2005]. The degree of
caspase 3/7 activation scaled to sunitinib dose logarithmically (log2; R2>0.99). Caspase
3/7 levels were found to peak at 8hr following treatment. We also detected increases in
the proportions of necrotic cells in microtissues treated with sunitinib (1.84±0.11 fold
higher than vehicle). These results suggested that our microtissue model was suitable for
detecting early changes in cardiomyocyte viability with sunitinib treatment.
Next we sought to assess changes in CMT function with sunitinib treatment. We
observed dose dependent decreases in diastolic and systolic tension with sunitinib
treatment. We could not discern whether observed decreases in systolic tension were due
to changes in resting sarcomere length, which is unlikely given the decreases in diastolic
tension we observed. Decreases in diastolic tension would tend to favor increases in tissue
(and sarcomere) length which by the Frank Starling principle would cause active tension
to increase. We also observed dose-dependent decreases in the spontaneous beating
frequency of microtissues treated with sunitinib. However, when microtissues were
subjected to field stimulation, we found no difference in electrophysiology parameters
such as excitation threshold and maximum capture rate. A major limitation we cited in
this group of experiments was the ability to distinguish whether the observed changes in
function are directly or indirectly due to sunitinib treatment. Specifically, is sunitinib
directly impacting force generation and beating frequency; or is the injury to myocytes
and apoptosis responsible for the decreases in function we observed? This is an important
consideration for all research groups utilizing multi-cellular preparations to assess drug
toxicity and its impacts on function. Nevertheless, the cardiac microtissue model appears
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to recapitulate many of the observed cardiotoxic effects of sunitinib cited in the literature
and clinic.
7.1.2 Elucidating the roles of mitochondrial dysfunction and increased mechanical
loading
The direct interaction between load and cardiotoxicity in the setting of sunitinib
has been uncertain. We hypothesized increased afterload will augment the cardiotoxic
effects of sunitinib. In addition to afterload, mitochondria dysfunction is thought to be
another mechanism for sunitinib cardiotoxicity given the evidence of mitochondria
swelling from patient biopsies [Chu et al. 2007]. However, mitochondria dysfunction as it
relates to sunitinib has not been fully characterized.
Chapter 5 began with characterizing changes in mitochondrial dynamics with
sunitinib treatment. Experiments with TMRM, an indicator of mitochondrial membrane
potential, we found modest yet significant decreases in mitochondrial membrane potential
in populations of cells treated with 1µM sunitinib after 4hr and 8hr of treatment.
Interestingly these time points corresponded with observed activation of caspases 3 and 7.
We related our findings of mitochondrial dysfunction with decreases (~30%) in cellular
ATP levels. A limitation of these studies was that they had to be performed in 2D flat
culture because technical factors precluded performing these experiments with cardiac
microtissues. Nevertheless, these experiments suggest that mitochondrial dysfunction
occur with sunitinib treatment.
The latter part of Chapter 5 focused on addressing the hypothesis that increased
afterload potentiates the cardiotoxic effects of sunitinib. We were able to create tissues
under varying degrees of afterload by altering the mechanical properties of the pillars on
which they form. Using caspase 3/7 activation as a primary metric for cardiotoxicity, we
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found that tissues grown on stiffer pillars exhibit a higher fold change in caspase 3/7
activation in response to sunitinib treatment compared to tissues grown on soft pillars
(2.91±0.21 stiff vs. 1.74±0.06 soft fold increase relative to vehicle; p<0.01). These results
demonstrate that afterload is a direct modulator of sunitinib induced apoptosis. Our results
suggest that management of hypertension may be important for preventing eventual LV
dysfunction in patients receiving sunitinib.

7.1.3 Evaluating the effects of sunitinib in CMTs composed of human cardiomyocytes
In the final part of this dissertation, Chapter 6, we examined the responses of
human CMTs to sunitinib using caspase 3/7 activation as our primary metric for
cardiotoxicity. We compared sensitivity of human and neonatal rat CMTs. We found that
human CMTs demonstrated increased caspase 3/7 activation in response to a
physiological dose sunitinib (1µM) similar to what we observed in neonatal rat CMTs.
This similarity suggests that the rat CMT model can capture some aspects of sunitinib
induced cardiotoxicity, such as changes in cell viability. Finally, we assessed how caspase
activation in response to sunitinib is impacted by afterload in human CMTs. Similar to rat
CMTs increased afterload augments sunitinib induced caspase 3/7 activation. However, in
contrast to rat CMTs, human CMTs cultured on soft pillars exhibited minimal caspase
activation in response to sunitinib. Our finding that increased afterload potentiates
sunitinib cardiotoxicity in both rat and human CMTs strongly supports our hypothesis
that increased afterload enhances sunitinib cardiotoxicity rather than simply unmasking in
vivo LV dysfunction.
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7.2 Clinical Implications of this Work
A key finding in this study was that afterload does not merely coincide with LV
dysfunction in patients but actually exacerbates sunitinib-induced cardiotoxicity.
Furthermore, our results with human CMTs demonstrate that a certain amount of
afterload is actually required to observe sunitinib induced apoptosis, and suggests that
management of hypertension may be important for preventing eventual LV dysfunction.
These human studies serve as the “in vitro analog” to findings in patients that
hypertension typically precedes or coincides with the development of LV dysfunction,
and increases the clinical relevance of this work. We believe that our findings with
afterload also demonstrate the need to develop more in vitro models, similar to our
cardiac microtissue model, that can manipulate mechanical forces, as our research
demonstrates that these forces play a role in chemotherapy induced cardiotoxicity.
Though our findings are not sufficient to change clinical guidelines for
managing/preventing hypertension and LV dysfunction in patients being treated with
sunitinib, we hope this work will inspire a clinical investigations specifically examining
whether intensive anti-hypertensive treatment can reduced the frequency and/or severity
of LV dysfunction in patients treated with sunitinib and perhaps other tyrosine kinase
inhibitors as well.
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7.3 Future Work
Most of our future work for the project will focus on further elucidating the role of
afterload in the context of sunitinib cardiotoxicity. Future experiments will utilize human
cardiac microtissues. We would like to expand our metrics for evaluating the effects of
sunitinib under varying degrees of afterload. Specifically we would like to include
experiments that measure force under varying degrees of afterload, in the presence or
absence of sunitinib. This will require us to be able to make force measurements at a fixed
tissue length, to account for any resting sarcomere length changes that may be occurring.
We are actively working to develop methods to control tissue length by inserting iron
particles in pillar caps and controlling pillar displacement with a magnet (Fig 7.1 panel
A). Additionally, we would like to be able to induce secondary increases in afterload in
our CMT model. We believe that this attribute would make our work more clinically
relevant as a secondary change in afterload is a better mimic of the secondary
development of hypertension in patients. Furthermore, if secondary increases in afterload
can be reversed, it would give us the opportunity to begin answering the question whether
sunitinib induced cardiotoxicity could be reversed by decreasing the amount of afterload
on the heart. To accomplish this, we plan on using magnetic particles, except in this case
the particles would be embedded in a very soft layer of PDMS at the bottom of the well.
The application of a magnetic field would cause the iron particle to align, resulting in the
hardening of the bottom layer, effectively shortening the pillars, thus increasing their
spring constants (Fig 7.1 panel B).
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Figure 7.1: Modifying the cardiac microtissue platform to study the effect of
afterload on cardiac function in the context of sunitinib. A) Making force
measurements at fixed tissue lengths by controlling pillar displacement with embedded
iron particles and magnetics. One pillar will be pulled with a magnet to control tissue
length by being, while the other pillar will report resulting forces. B) Secondary changes
in afterload are accomplished by embedding iron particles into a soft layer of PDMS on
the bottom of the wells. Under a magnetic field this bottom layer will harden
significantly, effectively shortening pillar length, thus increasing spring constant. Figure
credit: Elise A. Corbin, PhD.
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Another area for future work would be to study sunitinib in human CMTs created
from iPS lines from patients with different histories of cardiotoxicity from sunitinib.
Penn’s Cardiovascular Institute has access to blood samples from patients undergoing
chemotherapy, which could be used to generate iPSC lines (See section 2.3.2.2 for a
discussion on patient specific iPS-CMs). Specifically, we would like to test weather
iPSC-CM CMTs from patients who have experienced sunitinib cardiotoxicity have
greater in vitro susceptibility than iPSC-CM CMTs from patients without cardiotoxicity
despite higher exposures. If we are successful in those studies, than we would examine
whether gene editing can mitigate sunitinib cardiotoxicity (see section 2.3.2.2 for a
discussion on gene editing).
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